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Abstract
Ischemic stroke (IS) is a heterogeneous disease in which outcome is 
infl uenced by many factors. Th e hemostatic system is activated in association 
with cerebral ischemia, and markers measuring coagulation, fi brinolysis, 
and vasoactivity could be useful tools in clinical practice. However, previous 
studies have not determined these markers in a well-defi ned population of 
patients with IS, nor have studies included well-structured follow-up with 
repeated measurements.
Th e main purpose of this study was to identify changes in the activities 
of markers measuring coagulation, fi brinolysis, and vasoactivity in a 
population of patients with fi rst-ever IS. It was investigated whether repeated 
measurements of these markers reveal patterns that might help in evaluating 
IS patients, including the early diagnosis of stroke subtypes, in estimating 
prognosis and risk of recurrence, and in selecting a treatment for secondary 
prevention of stroke.
Markers assessing coagulation, fi brinolysis, and vasoactivity were 
measured in 102 consecutive mild to moderate IS patients on four occasions: 
on admission and at 1 week, 1 month, and 3 months aft er stroke, but only 
once in the control group. All patients underwent neurological examination 
and blood sampling in the same session. All patients were contacted 3 years 
later for prognostic determination. Vasoconstrictor peptide endothelin-
1 (ET-1), homocysteine (Hcy), indicators of thrombin formation and 
activation (prothrombin fragment 1+2/F1+2, thrombin-antithrombin 
complex/TAT), indicators of plasmin formation and fi brinolysis (tissue 
plasminogen activator/t-PA, plasminogen activator inhibitor-1/PAI-1, and 
D-dimer), and natural anticoagulants (antithrombin/AT, protein C/PC, 
and protein S/PS) were measured. Furthermore, 740 patients with clinically 
and radiologically confi rmed IS without an obvious etiology were screened 
for factor V Leiden mutation (FVLm). Forty-two IS patients with proven 
heterozygous FVLm were evaluated in detail for specifi c clinical, laboratory, 
and radiological features.
Repeated measurements of ET-1 levels did not disclose information 
that could aid in the diagnostic evaluation of IS patients (I). Increased 
local production of ET-1 may not be correctly detected in peripheral blood 
because ET-1 is a local regulating factor and is higher at the interface of the 
endothelium than in plasma. Measurement from the cerebral blood fl ow 
(CSF) during the hyperacute phase may deliver more accurate results. 
Plasma Hcy levels were signifi cantly lower in IS patients than in control 
subjects in the acute stage, increasing and remaining stable during the 
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convalescent period (II). Th is marked decrease in Hcy levels upon occurrence 
of IS may be a protective reaction of the human body aimed at limiting brain 
injury or may be a nonspecifi c acute phase reaction.
Th e follow-up examination of IS patients showed that F1+2 level at 3 months 
aft er stroke had a positive correlation with recurrence of thromboembolic 
events and may be used as a predictive marker of subsequent cerebral events 
(III). Th ese data support the idea that IS patients with sustained activation 
of the blood coagulation system and increased thrombin generation may 
have an unfavorable prognosis. 
Th e elevated D-dimer levels on admission and 1 week aft er IS were 
strongly associated with stroke outcome and disability (III). Elevated levels 
of D-dimer may refl ect the level of activation of both the fi brinolytic and 
coagulation systems, and, thus, the ongoing thrombotic process.
AT level on admission (IV) was signifi cantly correlated with stroke severity 
and outcome. Th ese results probably refl ect an increased consumption of 
active AT due to the extent of thrombosis. 
Th e specifi c analysis of IS patients with heterozygous FVLm (V) more 
oft en revealed a positive family history of thrombosis, a higher prevalence 
of peripheral vascular disease, and multiple infarctions in brain images, 
most of which were ‘silent infarcts’. Presence of FVLm in IS patients did not 
aff ect stroke severity or outcome.
In summary, results of this study suggest that changes in the markers 
measuring coagulation, fi brinolysis, and vasoactivity could be useful for 
predicting prognosis of IS patients. A clear need exists for a randomized 
prospective study to determine whether a subgroup of IS patients with 
markers indicating activation of the fi brinolytic and coagulation systems 
might benefi t from more aggressive secondary prevention of IS.
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Introduction
Th e property of the circulation whereby blood retains its fl uidity within the 
vasculature while the system simultaneously prevents excessive blood loss 
upon injury is known as hemostasis. Approximately 150 years ago, Virchow 
proposed that three anatomic compartments – blood fl ow, blood components 
(soluble and cellular constituents), and the blood vessel wall – are involved 
in a delicately orchestrated biochemical interplay which, under normal 
conditions, maintains the hemostatic equilibrium. Blood constituents do 
not normally interact with undamaged vascular endothelium. In response to 
vascular injury, clotting reactions are initiated to create an insoluble fi brin-
platelet plug, arrest blood loss, and eventually restore vascular integrity. Th e 
arterial fl ow condition produces platelet-rich (“white”) thrombi and static 
venous fl ow yield fi brin- and red cell-rich (“red”) thrombi. Disturbances are 
refl ected in functional changes in the endothelium, platelets, coagulation, 
or fi brinolysis that predispose to thrombus formation or hemorrhage, or 
sometimes both (35) (Figure 1).
Figure 1. Normal physiology of hemostasis. Adapted from Casey: Nurs Stand, Volume 
18 (7), 2003, 45–51.
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A large number of epidemiological and case-control studies have provided 
strong evidence of an association between activation of the hemostatic system 
and ischemic stroke. Several hemostatic markers have been measured in the 
acute as well as the chronic phase of IS. Some data have been published about 
early involvement of the hemostatic system in arteriosclerosis. Evidence exists 
of increased thrombin generation and fi brin turnover, altered fi brinolytic 
activity, and disturbed endothelial function in IS (16, 20, 21, 164, 259). 
However, most previous studies have included one-time measurements of 
markers of coagulation and fi brinolysis or measurement of only a limited 
number of factors.
Shift s in the balance of the hemostatic system may play an important role 
in the effi  cacy and safety of IS treatment. Markers measuring coagulation, 
fi brinolysis, and vasoactivity could potentially be used as indicators of the 
risk-benefi t ratio when patients are evaluated for thrombolytic therapy. Th ey 
could also explain the subsequent response to thrombolysis (241).
Th is study aimed to improve our understanding of the underlying 
mechanism of IS and to clarify how the course of IS infl uences changes 
in hemostatic balance. To this end, serial changes in markers measuring 
coagulation, fi brinolysis, and vasoactivity in patients aft er fi rst-ever IS were 
investigated. Further, we identifi ed whether measurement of these markers 
discloses patterns that might yield causative, prognostic, and preventive 
information useful in evaluation of IS patients.
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Ischemic stroke
Epidemiology
Stroke is a clinically defi ned syndrome of rapidly developing symptoms 
or signs of focal loss of cerebral function with no apparent cause other 
than vascular origin. However, the loss of function can at times be global. 
Symptoms of stroke last more than 24 h or may lead to death before this (11). 
Stroke is the third leading cause of death in developed world aft er coronary 
artery disease and all types of cancer combined. It causes 4.4 million (9%) of 
the total of 50.5 million deaths each year (112). In most Western populations, 
0.2% of the population (2000 persons per million) suff er a stroke each year, 
of whom one third die over the next year, one third remain permanently 
disabled, and one third make a reasonable recovery. Each year about 14 000 
people suff er a stroke in Finland, 5000 of whom die either acutely or during 
the fi rst year aft er the stroke (91).
In the past, Finland had one of the highest reported incidences of stroke 
in the world (17). Most studies have described a steady declining trend, but 
also an increase in stroke incidence during the 1960s and 1970s has been 
reported. Since the 1990s, however, the incidence of stroke has declined 
steeply (268). During a 10-year period (from 1988 to 1997) the incidence of 
IS in the Kuopio area fell by 5.2%/year in both men and women. Th e rates 
declined from 289 to 182 per 100 000 in men and from 158 to 99 per 100 
000 in women (235). In the FINSTROKE register population, the mortality 
rate fell during a 15-year period (1983–1997) from 85 to 51 per 100 000 in 
men (–3.7%/year) and from 50 to 30 per 100 000 in women (–4.1%/year) 
(235).
A signifi cant circadian rhythm has been observed for cerebrovascular 
disease (201). About one-third of all strokes occur in the morning between 
7 a.m. and noon (99).
As the most important cause of long-term disability, stroke has a 
considerable impact on public health. One-third of strokes occur in working-
aged people, being a more common cause of early retirement in Finland 
than ischemic heart disease in people under the age of 55 years. Stroke is 
a leading neurological reason for hospitalization, accounting for 29 000 
hospitalizations and 2 million bed-days annually in Finland (214). Th e 
overall direct and indirect costs of strokes were estimated to be as high 
as 440 million euros in 1999, i.e. 6.1% of the total national health system 
budget (214).
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Risk factors
Epidemiological investigations have identifi ed numerous IS risk factors. 
Th ese can be divided into two groups for practical reasons: nonmodifi able 
and modifi able risk factors. Age, sex, ethnicity, heredity, and family history 
of vascular disease have been established as nonmodifi able risk factors.
Aft er age, arterial hypertension (AH) is the most powerful stroke risk 
factor. Th e incidence of stroke rises in proportion with blood pressure. In 
the Framingham study, the relative risk of stroke for a 10 mm Hg increase 
in systolic blood pressure was 1.9 for men and 1.7 for women. A systematic 
overview of 14 prospective studies indicated that a decrease in diastolic blood 
pressure of 5–6 mm Hg reduces the risk of stroke by 42% (59). Cardiac disease 
is an important precursor of IS, particularly coronary artery disease, atrial 
fi brillation (AF), valvular heart disease, myocardial infarction, congestive 
heart disease, and left  ventricular hypertrophy. AF is associated with one of 
every six IS. In patients with AF, the annual risk of stroke is 1.3–6%. Stroke 
risk nearly doubles in those with coronary artery disease and quadruples in 
subjects with cardiac failure (219). Stroke aff ects 0.7–4.7% of patients aft er 
acute myocardial infarction (279).
Diabetes mellitus (DM) constitutes an independent risk factor for IS, with 
a relative risk ranging from 1.8 to 3.0 depending on type and severity. Data 
from the Framingham study suggested that subjects with glucose intolerance 
have an increased risk of IS by a factor of two as compared with nondiabetics 
(219). In the Honolulu Heart Study, the risk for thromboembolic stroke 
was lowest in persons with low-normal fasting glucose and increased with 
high-normal fasting glucose, asymptomatic high blood glucose, and DM, 
the latter of which was associated with the highest stroke risk (48).
Th e link between serum cholesterol level and the incidence of stroke is 
not fully established. A report from the Atherosclerosis Risk in Communities 
(ARIC) Study found only a weak and inconsistent association between IS 
and each of fi ve lipid factors in the 305 subjects experiencing IS aft er 10 
years of prospective investigation (231). In a meta-analysis of 45 prospective 
epidemiological studies comprising 450 000 subjects among whom 13 000 
strokes occurred, no signifi cant association between total serum cholesterol 
and total stroke incidence was seen (7). Despite the lack of association of 
blood lipids with incidence of IS, a signifi cant reduction in stroke incidence 
has been shown in a series of trials of statins in patients with coronary heart 
disease (5, 9, 207).
Obesity has been associated with higher levels of blood pressure, blood 
glucose, and atherogenic serum lipids (219). Obesity, as refl ected in body 
mass index (BMI), and waist circumference were related to stroke incidence 
(271). Smoking has been clearly linked to IS. Smoking cessation markedly 
reduces the increased risk of IS in two years, and the risk is nonexistent aft er 
fi ve years (144). Th e role of alcohol as a stroke risk factor depends on stroke 
subtype and the amount of alcohol consumed (51).
Review of the literature14
Pathophysiology
Th e brain is supplied by two major arterial systems. Much of the cerebral 
hemispheres are supplied by the carotid arterial system, whereas the entire 
posterior fossa, occipital lobes, and portions of the temporal lobes are 
supplied by the vertebrobasilar system. A series of anastomotic channels, 
including the circle of Willis located at the base of the brain, interconnect 
these two systems. Half of the brain weight and volume comprises gray 
matter and the other half white matter (275).
Cerebral blood fl ow (CBF) of the gray matter is about 80 mL and of 
the white matter about 20 mL/min/100 g brain tissue. CBF is normally 
maintained at a relatively constant rate by a process of autoregulation and 
can thereby compensate for a wide range of fl uctuations in perfusion pressure 
and cerebrovascular resistance. Ischemic strokes result from occlusion of an 
artery, preventing CBF to a specifi c area of the brain (45). Th e residual CBF 
depends on the degree of obstruction and the availability of collateral fl ow. 
Ultimately, the amount of injury is proportional to the duration and severity 
of the ischemia. As the amount of fl ow diminishes, the brain compensates 
by local vasodilatation, opening of collaterals, and increasing the fraction of 
extracted oxygen and glucose. When CBF is reduced below 18 mL/min/100 
g tissue, synaptic transmission stops and electrical silence ensues, thereby 
decreasing cerebral energy use by 50%. Aft er a further decline in CBF to 
below 8 mL/min/100 g, a series of events unfold (“ischemic cascade”). Th e 
process of metabolic failure leading to cell death involves insuffi  cient blood 
fl ow, loss of energy, and neuronal depolarization (45). Th e resultant release 
of glutamate, entry of Ca2+ into cells, generation of oxygen free radicals 
and nitric oxide, and activation of proteases and lipases all contribute to 
pathologic changes in neuronal function and structure.
If the normal protective mechanisms are insuffi  cient to compensate for 
this deprivation, death of tissue, i.e. infarction, develops (31). Th e primary 
injury results in an initial ischemic core. Th e CBF in the core is usually below 
25% of normal. Surrounding this core is an area of decreased blood fl ow 
(“ischemic penumbra”) that may be salvaged if blood fl ow is reestablished 
promptly. Th e CBF in the penumbra is approximately 25–50% of normal, 
which is suffi  cient to preserve energy metabolism and maintain tissue 
viability for a period of hours. Since autoregulation is lost in the area of 
ischemia and the ischemic region is perfusion-dependent, any decrease 
in systemic arterial blood pressure can extend the area of ischemia and 
infarction. If the state of low CBF continues, the penumbra zone or part of 
it may proceed to irreversible cell death (31).
Classifi cation
Approximately 80% of all strokes are ischemic, 10% are due to intracerebral 
hemorrhage, and the rest are due to subarachnoid hemorrhage. In IS, the most 
common pathophysiological bases in the majority of cases are atherosclerosis 
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of extra- and intracranial arteries (14–40% of all IS), cardiogenic embolism 
(15–30%), and penetrating small-artery disease (15–30%) (221). Stroke 
prognosis, recurrence risk, and management choices are infl uenced by IS 
subtype. Th e stroke subtype diagnosis guides treatment decisions and may be 
important for understanding diff erences in the impact of a given intervention 
in a clinical trial setting. Th ere is no universally accepted classifi cation of 
IS subtypes. Th e Trial of Org 10172 (danaparoid sodium, low molecular 
weight heparinoid) in Acute Stroke Treatment (TOAST) (13) classifi cation 
grades IS patients with regard to pathophysiology and etiology; it has been 
widely used in both prospective clinical trials and retrospective studies of 
patterns of care and stroke-related outcomes, and it provides information 
relevant to secondary prevention. Th ere are fi ve major categories of IS in 
the TOAST classifi cation: (1) large-artery atherosclerosis (LAA), including 
large-artery thrombosis and artery-to-artery embolism; (2) cardioembolism 
(CE); (3) small-artery occlusion (SAO); (4) stroke of other determined 
cause (OC); and (5) stroke of undetermined cause (UND). Strokes of 
undetermined origin required fulfi lling one of the following two criteria: 
(1) no cause was found despite an extensive evaluation or (2) a most likely 
cause could not be determined because more than one plausible cause was 
found. Th e subtype defi nitions were based on risk factor profi les, clinical 
features, and results of diagnostic tests. Th e latter included computerized 
tomography (CT) scan, magnetic resonance imaging (MRI), vascular imaging 
(carotid duplex, transcranial Doppler), electrocardiography (ECG), Holter 
recording, echocardiography (transesophageal or transthoracic), assessment 
of prothrombotic syndromes, and postmortem examination. In a recent 
study (146), the distribution of subtypes in a European population was as 
follows: LAA 13%, CE 27%, SAO 23%, OC 2%, and UND 35%. Frequency 
of infarct subtypes may diff er among populations depending on patient 
selection and geographic region. Th e Oxfordshire Community Stroke Project 
(OCSP) criteria categorize subtypes of IS primarily on the basis of vascular 
territory into four groups: total anterior circulation infarction (TACI), 
partial anterior circulation infarction (PACI), lacunar infarction (LACI), and 
posterior circulation infarction (POCI) (27). Th is classifi cation is reasonably 
predictive of etiology, prognosis, and the size and site of cerebral infarction 
with CT scan. Distribution of the IS subtypes among the patients in the 
OCSP emerged as follows: 17% had TACI (both cortical and subcortical 
involvement), 34% PACI, 25% LACI, and 24% POCI.
Clinical aspects
Th e main clinical feature of stroke is its acute onset. Th e symptoms produced 
refl ect the location and nature of the pathological process. Lesions involving 
the carotid system may alter function in the distribution of any of its three 
clinically important branches: opthalmic artery, anterior cerebral artery, and 
middle cerebral artery. Th erefore, the various combinations of hemiparesis, 
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hemisensory defi cit, monocular visual loss, and aphasia are suggestive of the 
lesion in this system. Lesions involving the vertebrobasilar system may alter 
function in the region of the cerebellum, the brainstem, and the occipital and 
temporal lobes via the posterior cerebral artery. Th e various combinations 
of diplopia, dysarthria, dysphagia, and disequilibrium associated with 
hemiparesis, hemisensory defi cit, or homonymous hemianopia are suggestive 
of a lesion in the vertebrobasilar system (255).
Clinical grading scales are important in the evaluation and management 
of patients with acute neurological disorders. In addition, these assessments 
are needed to identify those stroke patients at higher risk for early death, 
and to provide patients and their caregivers with more accurate prognostic 
information. Several scales have been developed to measure recovery and 
disability aft er acute stroke. Some of the most widely used scales are the 
Glasgow Coma Scale (GCS) (254), the National Institutes of Health Stroke 
Scale (NIHSS) (44), the Scandinavian Stroke Scale (SSS) (10), the Barthel 
Index (BI) (178), the modifi ed Rankin Scale (mRS) (274), and Mini-Mental 
Status Examination (MMSE) (92). Data about the neurological scores 
mentioned above are summarized in Table 1.
Table 1. Neurological scales.
Clinical grading scale  Measures Evaluates Points
Glasgow Coma Scale level of 
consciousness




of Health Stroke Scale
severity of stroke 
symptoms
level of consciousness, extraocular 
movements,  speech, language, visual 
fi eld defi cits, facial muscle function, 





severity of stroke 
symptoms
level of consciousness, motor 
function, disorders of cranial nerves, 
cutaneous sensitivity, gait, speech
0–58
Barthel Index self-care and 
mobility
bowel function, bladder function, 
grooming, toilet use, feeding, 
transfer, mobility, dressing, bathing
0–100




no symptoms – need for supervision 
or assistance with activities of daily 





cognition orientation, registration, attention, 
calculation, recall, language, 
visuospatial construction
0–30
Review of the literature 17
No single outcome measure can describe or predict all dimensions of 
recovery and disability aft er stroke, and each scale has a potential role in 
patient care and research.
Management
Pharmacotherapy
Th erapy for acute IS relies on the presence of brain tissue that is viable and 
salvageable. Th e infarct core requires almost immediate reperfusion if it is 
to be saved. Th e penumbra, which maintains viability for a longer time, is 
a natural target for medical intervention. Recent advances in thrombolytic 
therapy have made it possible to reopen occluded vessels. To date, only 
four modalities, intravenous t-PA, intraarterial prourokinase (proUK), 
ancrod (an intravenous defi brinogenating agent), and NXY-059 (disodium 
2,4-disulfophenyl-N-tert-butylnitrone, a nitrone with free radical trapping 
properties), have been shown in large prospective randomized studies to 
improve the outcome aft er acute IS (6, 97, 160, 232). Th ese agents must be 
administered within a very narrow time window aft er stroke onset (3 h for 
intravenous t-PA and ancrod, 6 h for intraarterial proUK and NXY-059), 
and only t-PA has been approved for use in this indication by the Food 
and Drug Administration (FDA) and the European Medical Association 
(EMA) (3). Th e option of thrombolytic therapy is available to a limited 
number of well-selected patients. Neuroprotection can be off ered to all 
stroke patients. Neuroprotective agents have the potential to reduce ischemic 
injury and improve stroke outcome. Despite several studies with various 
pharmacological agents, including N-methyl-d-aspartate antagonists, Ca2+ 
channel blockers, anti-infl ammatory antibodies, and intravenous magnesium, 
no neuroprotective agent has yet been demonstrated to have a conclusive 
benefi t in large prospective randomized effi  cacy trials on patients with acute 
IS, except NXY in one trial (43, 69). NXY-059 reduces the size of the infarct 
and preserves brain functioning in animal models of acute IS (152). A recent 
Stroke-Acute Ischemic NXY Treatment (SAINT I) study for acute IS showed 
a reduction in disability (160). Th e administration of NXY-059 within 6 h 
of the onset of acute IS signifi cantly improved outcome as measured by 
the modifi ed Rankin score at 90 days, but it did not signifi cantly improve 
other outcome measures, including neurologic functioning measured by 
the NIHS scale.
Anticoagulation in acute IS is a point of great controversy. Although the 
rationale for anticoagulation to prevent progression or recurrence of stroke 
is appealing, no study or meta-analysis has provided conclusive proof of a 
benefi t with heparin in acute IS. Despite this, heparin is commonly used 
in patients with cardioembolic stroke, large vessel stroke progression, and 
basilar artery thrombosis, and to prevent deep vein thrombosis (DVT) and 
pulmonary embolism (3).
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Stroke unit
Acute stroke patients should be treated in a stroke unit by a multidisciplinary 
team. General management of acute stroke includes monitoring and support 
of conditions that need to be stabilized (respiratory and cardiac care, fl uid and 
metabolic management, arterial blood pressure control, glycemic control, 
and treatment of elevated intracranial pressure) as well as prevention of 
DVT and pulmonary embolism and treatment of infections and seizures 
(3). Rehabilitation begins at the acute phase of stroke and continues aft er 
discharge (141). A meta-analysis by the Stroke Unit Collaboration (3) showed 
an 18% relative reduction in mortality and a reduction in death and need for 
institutional care when patients were treated in a stroke unit as compared 
with a general medical ward. All types of patients with stroke benefi t from 
treatment and rehabilitation in stroke units: males and females, the young 
and elderly, and those with mild, moderate, and severe stroke.
Future of stroke care
Future directions in the critical care management of acute IS are anticipated 
to encompass fi ve main areas: reperfusion (thrombolysis and manipulation 
of systemic circulation to augment cerebral blood fl ow), neuroprotection, 
their combination, hypothermia, and decompressive surgery. At the moment, 
no specifi c neuroprotective strategy is in routine use, but several are under 
development. Multimodal approaches, such as magnesium administration, 
which has a wider safety margin, are also being investigated. Moreover, 
interest has increased in hemispheric decompression and hypothermia in 
large hemispheric stroke. Th is strategy may allow patient survival but it was 
oft en associated with substantial neurological defi cit. Recently, emphasis 
has been placed on the development of combined acute and rehabilitation 
stroke units, which seems promising in terms of reduced mortality and 
disability (3).
Prevention of stroke recurrence
Th e risk of recurrent stroke aft er a fi rst IS is high and depends on the etiology. 
Recurrent stroke risk from AF has been reported to be 12% per year (2), 
and among patients with intracranial atherosclerosis may be as high as 10% 
per year (57). Th ere are many strategies for lowering this risk. Th ese include 
management of such risk factors as high blood pressure, diabetes mellitus, 
dyslipidemia, medical treatment with anticoagulation or antiplatelet agents, 
and surgical or endovascular intervention. Th e choice of therapy should 
be tailored to the specifi c stroke subtype, its etiology, and the condition of 
the patient.
Antithrombotic treatment
Certain drugs can inhibit the basic processes of platelet aggregation and 
release reaction. Platelet-vessel wall interaction is infl uenced by the selective 
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oxygenation of arachidonic acid in both the platelets and the vascular 
endothelium. In the platelets, thromboxane synthase converts prostaglandin 
H2 to thromboxane A2, which is a potent aggregator of platelets as well as 
a constrictor of arterial conductance vessels. Th e vascular endothelium, 
however, metabolizes prostaglandin H2 to prostacyclin, which antagonizes 
platelet aggregation and dilates blood vessels. Th ese observations suggest 
that pharmacological agents that selectively inhibit thromboxane synthase or 
facilitate the biosynthesis of prostacyclin might be benefi cial in preventing 
the thrombotic complications of atherosclerosis.
Th e use of aspirin, clopidogrel, and dipyridamole in various combinations 
in treatment of IS patients has been evaluated in large trials(1, 75, 76). 
While there appears to be no major diff erences between these three drugs, 
the ESPS-II trial verifi ed the superiority of the combination of aspirin 
with extended release dipyridamole over aspirin alone (76). Combined 
aspirin and clopidogrel slightly reduces the risk of IS recurrence but 
increases bleeding risk over clopidogrel alone (75). In the absence of 
contraindications, anticoagulation should be planned for patients with high 
risk of cardioembolism in stroke prevention (3).
Invasive treatment
Carotid endarterectomy has been shown to be superior to medical treatment 
for the secondary prevention of IS in patients with high-grade carotid artery 
stenosis. A recent systematic review by the Cochrane Collaboration showed 
carotid endarterectomy to be the most eff ective treatment measure in terms 
of reduction of stroke recurrence or death in patients with symptomatic 
stenosis >50% and surgical complications <6% (58). Angioplasty and stenting 
therapy constitute promising new options in the management of patients 
with carotid atherosclerotic disease (140).
Outcome following
Development of novel strategies of IS treatment and prevention requires 
elucidation of stroke outcome, including death and stroke recurrence. Th e 
greatest risk of poor outcome and death for patients with IS occurs in the 
fi rst 30 days, with case-fatality rates ranging from 8% to 20% (278). Aft er 
one month, cardiovascular disorders, stroke, and diseases resulting from 
stroke were the causes of death in up to 80% of patients. Th e one-year 
mortality ranges from 20% to 35% (168). In the Framingham Study, the 
fi ve-year mortality rates aft er atherothrombotic brain infarction were 44% 
for men and 36% for women (222). Poor outcome may still occur because IS 
is a heterogeneous disease in which outcome is infl uenced by many factors, 
including concomitant diseases. Th e great variability in outcome in stroke 
patients has led to interest in identifying predictors of outcome through 
the use of prediction models. Many predictors have been reported to have 
a relationship with outcome. Nonmodifi able factors, such as age, gender, 
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and race-ethnicity, have been identifi ed as potential determinants of stroke 
outcome. Older patients are less likely to recover than young patients with 
similar-sized infarcts (120). A study of a large cohort of patients with IS 
treated with thrombolytic agents identifi ed signifi cant correlations between 
age, outcome, and bleeding complications. Older IS patients were less likely 
to have a good outcome even when receiving intravenous t-PA (71).
Th e two main cerebrovascular risk factors that infl uence outcome are 
AF and DM. Strokes in patients with AF are usually more severe, more 
disabling, and associated with a higher mortality (68, 134). IS patients with 
DM have a higher risk of death and disability aft er stroke (135, 186). Among 
clinical fi ndings, severity of stroke has been found to be one of the major 
predictors of poor outcome in many studies (191). Th e baseline NIHSS 
score strongly predicted mortality and functional outcome in the TOAST 
trial; one additional point on the baseline NIHSS score decreased by 24% 
the likelihood of survival and excellent outcome at 7 days and by 17% at 3 
months (14). Markers of initial stroke severity, such as decreased level of 
consciousness, gaze deviation, headache, nausea, or vomiting, may predict 
poor outcome in clinically severe strokes (148). Stroke subtype also seems 
to predict outcome. Small-vessel disease is more frequently associated with 
favorable outcome than IS of cardioembolic and large- vessel atherosclerotic 
cause. In these categories, 63%, 47%, and 29% of patients, respectively, have 
a favorable outcome (8). Some markers of tissue injury or infl ammation have 
been shown to predict a poor outcome aft er stroke. High glutamate levels 
strongly correlated with large infarct size and severe neurological defi cit (55). 
Increased serum levels of S-100 also correlate with neurological outcome 
(12). CRP elevation within 12–72 hours of stroke is associated with a high 
risk of death. Patients with CRP levels above 10.1 mg/L had signifi cantly 
worse likelihood of survival (190).
Recurrent stroke is a major cause of morbidity and mortality among stroke 
survivors. Large prospective studies indicated that the risk of recurrence aft er 
stroke varies from 1.7% to 4% in the fi rst 30 days, from 6% to 13% in the fi rst 
year, and from 5% to 8% per year for the next 2–5 years, culminating in a 
5-year cumulative risk of stroke recurrence of 19–42% (49, 116). Prognostic 
factors for recurrent stroke are clinically important because they may help 
to identify patients at high recurrence risk and provide insights into ways 
of improving outcome. IS subtype has been found to be associated with 
stroke recurrence. In the Rochester Epidemiology Project, IS due to large-
vessel atherosclerosis with stenosis had a higher risk of early recurrence. 
More than 18% of patients with this stroke subtype had a recurrent stroke 
within 30 days of the fi rst stroke (206). Stroke risk factors (age, AH, cardiac 
disease, and DM) have a great eff ect on risk of recurrence (217). Evidence 
for the relationship between IS recurrence and infl ammatory and hemostatic 
markers is also accumulating (241). Possible biochemical predictors of 
recurrent thromboembolic events include elevated C-reactive protein (CRP), 
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fi brinogen, and homocysteine (Hcy) levels (73). 
Although the risk of poor outcome and new vascular events aft er fi rst-
ever stroke is high, prediction of death or recurrence of vascular events 
is diffi  cult on an individual level. Discrepancies in identifying predictors 
of stroke outcome and recurrence have been observed. Th ese may result 
from the patient population selection, including age, comorbidity, and 
stroke subtype, the defi nition of the predictors used in the studies, and the 
duration of follow-up. Most likely, our ability to predict stroke outcome 
and recurrence will improve with further developments in technology and 
laboratory methods.
Hemostasis and thrombogenesis
Hemostasis is a physiological process initiated when damage occurs to 
a blood vessel wall and culminates in the formation of a stable clot that 
prevents the escape of further blood from the vessel. Th is occurs in three 
stages: vasoconstriction, platelet response, and blood coagulation. A fourth 
stage occurs when the clot is dissolved following repair of the blood vessel 
(54) (Figure 1). In vasoconstriction, injury to the blood vessel wall triggers 
a refl ex contraction of the circular layers of smooth muscle surrounding the 
endothelium. Th is action compresses the blood vessel to minimize blood loss 
and may continue for several minutes to some hours, and is enhanced by 
the release of platelet factors. Th is is not a permanent solution so the other 
phases of hemostasis are required to complete the process and to initiate 
eff ective blood vessel repair (54). Formation of an initial platelet plug is a 
complex series of responses by platelets, leading to generation of a clot at the 
site of the vessel wall defect. Platelet membrane glycoproteins are activated 
by contact with collagen in the wall of the damaged vessel. Th e process of 
binding to extravascular matrix proteins activates platelets. Th is activation 
leads to changes in the shape of the platelets, from a disc form to a compact 
sphere, and to the release of the various substances and proteins needed in 
platelet aggregation and initiation of coagulation reactions. Aft er primary 
hemostasis, i.e. instant vasoconstriction and formation of initial platelet 
plug, activation of the coagulation system is needed to stabilize the loose 
accumulation of platelets by cross-linked fi brin (121).
Endothelial functions and endothelin-1
Endothelium constitutes the structural and functional interface between 
blood and the vascular wall. Th e anatomic location of endothelium, its 
expansive interactive surface area, and the magnitude of endothelial tissue 
mass contribute to its functional roles as a selectively permeable, blood-
compatible, secretory membrane that regulates infl ammatory, vasomotor, 
growth factor, and hormonal responses. An important function of intact 
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endothelium is limitation of thrombus extension through the inactivation 
of thrombin activity, the reduction in thrombin generation, and the 
production of antithrombotic and vasodilating factors such as prostacyclin 
and nitric oxide. Endothelial cell activation results from stimulation of 
endothelial cells by excessive shear stress, injury, increased turbulence, or 
infl ammation. Mechanisms that maintain the thromboresistance properties 
of the endothelial surface may then be lost (179).
Th e endothelium produces potent vasoconstrictors, endothelins (ETs). 
Th eir powerful and long-lasting vasoconstrictive action has been documented 
in several species (286). Th ere are three structurally and pharmacologically 
separate ET isopeptides: ET-1, ET-2, and ET-3. All contain 21 amino acids 
and two sulfi de bonds, but ET-1 diff ers from ET-2 by two and from ET-3 by 
six amino acids (125). ET-1 is produced by vascular endothelial cells, ET-2 is 
present in the kidney and jejunum, and ET-3 occurs in the adrenal glands, 
jejunum, and kidney (105). ETs act through specifi c receptors with at least 
two distinct types: ETA and ETB. ET receptors occur in many diff erent organs, 
including the central nervous system (216). Within the brain, large variations 
exist in receptor concentration, with high concentrations occuring in the 
brainstem and cerebellum (247). ETA receptors are present on smooth muscle 
cells and in the heart, whereas ETB receptors are located on endothelial 
cells and in the central nervous system (30). ET-1 is derived from peptide 
precursor, preproendothelin-1, which is subsequently cleaved to “big” ET 
and then to active ET-1 (286). Experiments with smooth muscle cells suggest 
that ET-1 acts on the ETA, causing increases in Ca2+ concentration, which 
leads to contraction of smooth muscle cells and vasoconstriction.
ETs have many important physiological functions and are probably 
involved in the pathophysiology of numerous disease processes. ET-1 
is likely the most relevant form in cardiovascular disease, whereas ET-
3 is a neuropeptide; the role of ET-2 remains unclear (243). Due to its 
vasoconstrictor capacity, the potential role of ET-1 in the pathogenesis of AH 
has been discussed. Patients with hypertension show elevated levels of ET-1 
in the cerebrospinal fl uid and plasma (62, 196), although perfectly normal 
ET-1 levels have also been observed (226). Secretion of ET-1 is stimulated 
by insulin in human endothelial cells (90). Some studies have reported 
a positive, strong association of ET-1 level with DM (78, 204), but other 
studies have found no correlation (137). Dyslipidemia as well as obesity, 
sleep apnea, and smoking have been associated with elevated ET-1 levels, 
proposed to refl ect damage to endothelial cells and endothelial dysfunction 
(107, 180, 204, 218).
Th e ability of ET-1 to overwhelm homeostatic mechanisms that 
maintain CBF has attracted interest in its role in the cascade leading to IS. 
In addition to its eff ects on vascular tonus, ET-1 increases blood-brain barrier 
permeability (242). A recent study by Matsuo et al. (184) demonstrated 
that administration of an ETA receptor antagonist during reperfusion aft er 
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transient middle cerebral artery occlusion signifi cantly attenuated edema 
formation and mortality of animals aft er cerebral ischemia. Th is supports the 
involvement of ET-1 in the pathophysiology of acute IS. Local application 
of ET-1 has been shown to induce neuronal damage (177). Intraventricular 
administration of ET-1 in rats reduced CBF and led to the development of 
brain infarction (280). In normal conditions, circulating ET-1 levels are very 
low (105). An increase in plasma ET-1 levels occurs in various animal models 
of global and focal ischemia (30). Several clinical studies have measured 
plasma and cerebrospinal fl uid ET-1 levels in various subtypes and phases 
of IS (20, 23, 86, 155, 289). At the acute stage, ET-1 levels were reported to 
be elevated (86, 289) or normal (20, 155). In the chronic stage, ET-1 levels 
were increased (23).
Th e causes of the stroke-associated increase in plasma ET-1 levels remain 
unclear. A variety of factors have been proposed to cause the increased ET-1 
levels in IS. One of these may represent a nonspecifi c enhancement of ET-
1 production by systemic vascular endothelium in response to the stress 
associated with acute ischemia (280). Th e increased ET-1 production may be 
attributable to stress-induced release of acute-phase reactants (38). A second 
explanation is that cerebral ischemia is associated with hypercoagulability 
and platelet hyperactivity. Activated platelets accelerate preproendothelin 
production via local accumulation factors such as thrombin (40). A third 
possible explanation is that the source of increased ET-1 levels may be IS 
itself. Bian et al. (34) demonstrated elevated ET-1 levels in the ischemic 
brain region and in plasma aft er middle cerebral artery occlusion in 
rabbits. Ischemic damage may increase the leakage of ET-1 from injured 
endothelial cells of the involved cerebral microvessels (174). However, the 
relationships between plasma ET-1 levels, stroke pathogenesis, recurrence 
of thromboembolic events, and prognosis remain obscure.
Homocysteine
Hcy is a sulfur-containing amino acid formed during the metabolism 
of methionine that is further metabolized by one of two main routes, 
methylation and trans-sulfuration (114). Th e trans-sulfuration pathway 
involves the enzyme cystathione-beta-synthase (CBS), the action of which 
results in the condensation of Hcy with serine to form cystathionine using 
vitamin B6 as a cofactor (114). Th e remethylation of Hcy to methionine 
by the enzymes methionine synthase and methionine synthase reductase 
requires vitamin B12 as a cofactor and 5-methyltetrahydrofolate as a 
cosubstrate (formed from 5,10-methylenetetrahydrofolate by the enzyme 
5,10-methylenetetrahydrofolate reductase (MTHFR)) (114). Human plasma 
contains reduced and oxidized Hcy. Th e reduced form is called homocysteine, 
and the oxidized form homocystine. Th e oxidized form comprises 98–99% 
of total human plasma Hcy, 80–90% of which is bound to protein (16).
A great number of environmental factors have been found to play a 
Review of the literature24
determinant role in Hcy levels (126). Lussier-Cacan et al. (175) determined 
that Hcy level in women is 21% lower than in men. Hcy levels increase with 
age, as has also been found in previous studies (197, 260). Race or ethnic 
origin is another determining factor. Ubbink et al. (269) demonstrated 
that black South Africans had lower Hcy levels than white South Africans, 
although their diets were similar. It is likely that this diff erence is confi ned to 
genetic diff erences within groups. Th e most common genetic alteration that 
results in severe homocysteinuria is reduced CBS activity (74), and the most 
common genetic defect associated with mild homocysteinemia is a MTHFR 
gene mutation (70). Diet defi ciencies and folic acid, vitamin B6, or vitamin 
B12 malabsorption have been linked with hyperhomocysteinemia (270). A 
rise in Hcy level is associated with smoking, alcohol consumption, and high 
intake of coff ee (197). High Hcy levels exist in the following conditions: DM, 
AH, dyslipidemia, and sleep apnea (158, 202, 205, 209).
Th e hypothesis that high levels of Hcy acts as an atherogenic and 
thrombogenic risk factor leading to atherosclerosis was presented more 
than 30 years ago (185). Th ere probably is a multifactorial eff ect, the main 
consequences of which are endothelial and vascular wall damage and changes 
in procoagulant substances. Hcy can cause endothelial cell damage by 
promoting peroxide formation and impending its activation (118). Tawakol 
et al. (253) described defective endothelium-dependent vasodilatation in 
mildly hyperhomocysteinemic subjects. Hcy also stimulates the proliferation 
of vascular smoothmuscle cells, presumably thereby contributing to 
neointimal thickening (266).
Many studies have shown that an elevated Hcy level is an independent 
risk factor for cardiovascular disease (42, 83). It remains to be determined 
whether the relationship is causal or whether it is confounded by factors 
associated with high Hcy, such as current smoking, elevated arterial blood 
pressure, cysteine defi ciency, or even acute vascular events themselves, 
whereby the tissue damage may temporarily increase plasma Hcy levels 
(113). Th e link between Hcy and vascular diseases has been speculated to 
be mediated in part by activation of coagulation (106).
A correlation between elevated Hcy levels and risk of IS has also been 
proposed, but studies have given confl icting results (19, 122, 138, 149, 163, 
188). Th e risk of IS associated with Hcy level was signifi cantly weaker in 
prospective studies than in retrospective studies, which may refl ect bias in 
the latter because of diffi  culties in selecting controls or the eff ect of changes 
in treatment, renal function, or other factors aft er the onset of disease (4). 
Results of several large prospective trials have shown no preventive benefi t 
of the use of folic acid and vitamin B12 in patients with established vascular 
disease and mild hyperhomocysteinemia (4, 39, 261).
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Platelets
Platelets are an essential part of the physiologic hemostasis. Th ey are derived 
from stem cells in the bone marrow by fragmentation of megakaryocyte 
cytoplasm. Th rombopoietin is the dominant hormone controlling 
megakaryopoiesis and thrombopoiesis (143). Platelets are anucleate cells 
with diameters of 2–4 μm. Each day, an adult human produces approximately 
1 x 1011 platelets. A normal platelet count, 150–350 x 109/L, is essential for 
hemostasis. Platelets survive for about 10 days on average; younger platelets 
have greater functional ability. Th e spleen continually sequesters circulating 
platelets. Th e liver has also been suggested to be an important site of platelet 
destruction (100).
Under normal conditions, platelets are at rest and fl ow through blood 
vessels without interacting with any other cells. Th ey respond to vessel wall 
injury, alternations in blood fl ow, or chemical stimuli with the activation 
of a functional triad (adhesion, secretion, and aggregation) that leads to 
formation of a rapidly enlarging platelet thrombus (Figure 2). Vessel injury 
exposes subendothelial von Willebrand factor (vWF) and collagen to the 
circulating blood. Platelets have a range of surface membrane receptors 
that interact with these constituents, helping platelets to attach to target 
sites (283). Platelets adhere to the site of injury via a glycoprotein (GP) 
Ib/IX/V and Ia/IIa complex. Adherent platelets become activated. Th ese in 
turn cause activation of various receptors and release of two potent platelet 
agonists, thromboxane A2 (TXA2) and adenosine diphosphate (ADP), 
which bind to specifi c platelet receptors, resulting in a change in form, 
from the normal disc shape to a compact sphere with irregular extending 
pseudopodi, secretion of granular contents, and promotion of platelet-
platelet interaction (aggregation) (283). Aggregation is mediated by GP IIb/
IIIa receptors on the platelet surface that bind various adhesion proteins. One 
of the most important adhesion proteins is fi brinogen. Binding of fi brinogen 
and VWF to GP IIb/IIIa receptors results in a thrombin-mediated conversion 
into fi brin and thrombus formation. Th is process can be attenuated by 
endothelial or platelet release of nitric oxide (NO). Th e morphologic changes 
are accompanied by redistribution of the phospholipids in the platelet 
membrane, building a surface for coagulant protein molecules (94).
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Figure 2. Platelet adhesion and aggregation. Damage of vascular wall exposes 
subendothelial von Willebrand factor (VWF) and collagen to the blood. Platelets 
adhere to the site of injury when glycoprotein (GP) Ib/IX/V and Ia/IIa complexes 
expressed on the platelet surface bind to VWF and collagen, respectively. Th is 
event triggers the synthesis and release of thromboxane A2 (TXA2) and adenosine 
diphosphate (ADP) and causes activation of various receptors (R). Conformational 
changes in GP IIb/IIIa follow, enabling high-affi  nity binding of fi brinogen and VWF, 
resulting in thrombus formation. Th is process can be attenuated by endothelial or 
platelet release of nitric oxide (NO). Adapted from Freedman: Circulation, Volume 
112, 2005, 2725–2734.
Coagulation system
Th e coagulation process is referred to as a cascade because each factor in the 
process acts on many molecules in the next stage of the process (Figure 3). Th e 
blood coagulation system is composed of inactive precursors of coagulation 
enzymes and cofactors, which become activated and then activate the next 
enzyme in the chain. Even though an initial stimulus may be small, a large 
quantity of the fi nal factor, fi brin, is produced (54). Coagulation at sites of 
disruption of the vessel wall occurs in three overlapping phases. 
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Figure 3. Steps in the coagulation cascade. Th e initiation of coagulation is triggered 
by the tissue factor/factor VIIa complex (TF/VIIa), which activates factors IX and  X. 
Activated factor IX (IXa) propagates coagulation by activating factor X in a reaction 
that utilizes activated factor VIII (VIIIa) as a cofactor. Activated factor X (Xa) with 
activated factor V (Va) as a cofactor converts prothrombin (II) to thrombin (IIa). 
Th rombin then converts fi brinogen to fi brin. Adapted from Weitz: Chest, Volume 126 
(3), Supplement, 2004, 265S–286S.
Th e process is initiated by exposed tissue factor (TF), which forms a complex 
with activated factor VII (FVIIa) (165). Low concentrations of FVIIIa 
circulate in the plasma so that the system is primed pending TF exposure. 
Th e FVIIa-TF complex then activates factor IX (FIXa) and factor X (FXa), but 
FX activation is more effi  cient. FXa cleaves small amounts of prothrombin 
to generate thrombin. A low concentration of thrombin enhances adhesion 
of platelets at the site of injury and activation of factor V (FVa), factor VIII 
(FVIIIa), and factor XI (FXIa). Aft er the platelets have been activated and 
activated FV and FVIII have bound to their surfaces, propagation and large-
scale thrombin generation begin. In the presence of calcium, FIXa binds 
to FVIIIa on the surface of activated platelets, thereby forming intrinsic 
tenase, the complex that activates FX (FXa). FXa then binds to FVa on the 
activated platelet surface to form the prothrombinase complex. Th is complex 
activates prothrombin (FII) on the phospholipid membrane through two 
sequential cleavages, yielding thrombin and prothrombin fragment 1+2 
(F1+2) (Figure 4).
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Figure 4. Factors of the coagulation and fi brinolysis systems and their interactions. 
Th in lines indicate inhibition/inactivation. Measured markers assessing coagulation 
and fi brinolysis are marked as ovals. Adapted from Godsland: Drugs, Volume 60 (4), 
2000, 721–869.
Th rombin then dissociates from the platelet surface and converts fi brinogen 
to fi brin, the fi nal step in the coagulation process. Th rombin also activates 
factor XIII (FXIIIa), which stabilizes the platelet/fi brin thrombus by cross-
linking the fi brin network, thereby rendering it more resistant to lysis 
(165).
F1+2 is a marker of thrombin generation. For each molecule of thrombin 
produced, one F1+2 molecule is cleaved from prothrombin (129). Th us, F1+2 
refl ects in vivo thrombin formation and may provide an important diagnostic 
tool in the evaluation of hypercoagulable states and in the diagnosis of 
diff erent clinical conditions related to thrombotic phenomena. In previous 
studies, increased F1+2 levels have been associated with conventional 
vascular risk factors such as advanced age, AH, DM, smoking, increased 
body mass index, sedentary lifestyle, family history of ischemic heart disease, 
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and dyslipidemia (173, 193, 282). A cohort study performed in Sweden 
demonstrated that F1+2 levels predict coronary morbidity in hypertensive 
patients (15). Because thrombin, a central enzyme in the coagulation cascade, 
plays a role in atherosclerosis progression, measurement of plasma levels of 
F1+2 might be of value in identifying of patients at high vascular risk who 
may benefi t from prophylactic antithrombotic strategies.
Several studies have found elevated plasma levels of F1+2 to be associated 
with the presence and severity of atherosclerotic disease (101, 200). However, 
a prospective study reported no association between F1+2 and risk of 
future cardiovascular events (263). Whether F1+2 levels are associated 
with increased IS risk has not been established (61, 96, 240). Studies in AF, 
a model of thromboembolism, provide some insights. F1+2 levels are higher 
in AF patients than in non-AF stroke patients or control subjects with a sinus 
rhythm (239). Th e etiology of increased thrombin generation in patients with 
cerebrovascular disease remains unclear. Th rombin generation is directly 
related to thrombus formation, and thus, refl ects secondary hemostatic 
activation due to infl ammation and endothelial injury associated with 
atherosclerosis. 
In the fi nal process of thrombus formation, thrombin acts with 
fi brinogen to form an insoluble fi brin clot, a step which may be inhibited 
by natural anticoagulant antithrombin. Antithrombin binds to thrombin 
(Figure 4) to form an irreversible thrombin-antithrombin complex 
(TAT) that refl ects, similar to F1+2, generation of thrombin in vivo. Data 
concerning the relationship between vascular risk factors and TAT levels 
are controversial (52, 102, 172, 282). TAT levels have been proposed as a 
marker of atherothrombotic risk (145). Some evidence indicates that TAT 
levels increase in peripheral arterial occlusive disease (PAOD), particularly 
in patients with recent symptom onset, which may represent an embolus 
rather than a thrombosis (203). Lassila et al. (156) found that TAT levels 
were associated with the extent of PAOD, possibly refl ecting coagulation 
activation and fi brinolysis.
Both elevated and normal TAT levels have been observed in IS patients 
(272). In IS patients with atherothrombotic or cardioembolic infarct, TAT 
levels have been reported to be increased (142, 195, 262), while no elevation 
of TAT levels was noted in patients suff ering from lacunar infarcts (248, 
249). No relationship between TAT levels and recurrence of IS has been 
found (47). However, Soncini et al. did show higher mortality in IS patients 
with increased TAT levels (240). Elevated TAT levels in IS might refl ect the 
presence of ongoing thrombosis within cerebral vessels or may be a marker 
of systemic hypercoagulability (142).
Regulation of coagulation
Coagulation is regulated via three inhibitory systems. Tissue factor pathway 
inhibitor (TFPI) targets the initiation of coagulation, antithrombin blocks 
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thrombin generation and thrombin activity, and protein C inhibits the 
propagation of coagulation.
Figure 5. Schematic diagram of regulation of coagulation. Formation of a clot is highly 
regulated by natural anticoagulant mechanisms that confi ne the hemostatic process 
to the site of injury on the vessel. Th in lines indicate inhibition/inactivation. Adapted 
from Nesheim: Chest, Volume 124 (3), Supplement, 2003, 33S–39S.
Tissue factor pathway inhibitor (TFPI)
Tissue factor pathway inhibitor (TFPI) blocks FVIIa in a two-step fashion. 
TFPI fi rst binds and inactivates FXa, and the TFPI/FXa complex then 
inactivates FVIIa bound to tissue factor. Circulating levels of TFPI are low, 
suggesting that the system is designed to block uncontrolled activation 
of coagulation by the FVIIa/tissue factor (TF) complex, while allowing 
propagation of coagulation by intrinsic tenase (Figure 5). Propagation 
of coagulation is ensured because thrombin activates FXI on the platelet 
surface, where it is poised to activate platelet-bound FIX (129).
Antithrombin
Th e most important direct inhibition mechanism of coagulation is 
neutralization of thrombin and factor Xa by antithrombin (AT) (Figure 
5). AT is synthesized in the liver. It was described as a protein required 
for antithrombotic activity of plasma (229). AT inhibits all coagulation 
proteinases (thrombin, FIXa, FXa, FXIa, and FXIIa), but not FVIIa and FVa. 
Arginine-rich centers in AT react irreversibly with the serine center of serine 
proteases. Complex formation between AT and its target enzymes is enhanced 
by heparin, which binds to lysyl residues on AT, making the critical arginine 
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residue more available for interaction with thrombin. Bound by heparin, 
the heparin-AT complex inhibits activated serine proteases with >1000-fold 
greater effi  cacy than AT alone (36). Egeberg et al. (80) fi rst established an 
association between AT defi ciency and recurrent venous thrombosis in a 
Norwegian family. Patients with AT defi ciency have a high risk of developing 
venous thrombosis, and the risk increases with age (256).
Protein C pathway
Protein C (PC) is a vitamin K-dependent protein that is synthesized primarily 
in the liver, kidneys, and male reproductive organs (85). Designed to regulate 
thrombin generation, the PC pathway is initiated when thrombin binds to 
thrombomodulin, its receptor on the endothelial cell surface. Th is forms the 
thrombin/thrombomodulin complex, which then activates PC by cleaving a 
single arginine residue. Th e binding of thrombin to thrombomodulin results 
in a ~1000-fold increase in the activation of protein C to activated protein C 
(APC). Activated protein C functions as an anticoagulant by proteolytically 
degrading and inactivating FVa and FVIIIa (Figure 5), thereby attenuating 
thrombin generation (85). Th e inactivation of FVa by APC has been reported 
to be enhanced by heparin and inhibited by prothrombin and Hcy (234).
Degradation of FVa by APC is markedly enhanced by protein S (PS). PS, a 
vitamin K-dependent single-chain glycoprotein, circulates in the blood as an 
active free protein and in nonconvalent association with a large, multisubunit 
protein of the complement system, C4bBP, in an inactive state (117). PS is 
expressed in many tissues, including the liver, endothelium, testis, brain, and 
megakaryocytes. Th e principal anticoagulant activity of PS is the inhibition 
of thrombin generation by acting as a cofactor to APC in the degradation of 
FVa and FVIIIa (Figure 5) and independently inhibiting the prothrombinase- 
and FX- activating complexes. PS may also play a role in vascular injury 
repair and in bone development (234). PS specifi cally enhances the rate of 
APC cleavage at Arg306 by inducing a conformational change and reducing 
the distance of the APC active site from the phospholipid surface. In the 
absence of PS, APC inactivation of FVa on the phospholipid surface is 
biphasic, with the fi rst and most rapid cleavage occurring at Arg506, and 
slow proteolysis at Arg306, resulting in complete loss of activity (215).
To date, several factors correlated with levels of natural anticoagulants have 
been identifi ed: age, gender, race, body mass index, DM, AH, dyslipidemia, 
smoking, and sleep apnea (213, 273, 282). Although defi ciencies in natural 
anticoagulants are responsible for up to 20% of nontraumatic venous 
thrombosis (267), arterial thrombosis has not been prominently associated 
with defi ciencies in these factors (251), except in single case reports or small 
series of young patients with cerebral infarctions of unknown origin (29, 
182). Studies of the relationship between levels of natural anticoagulants 
and risk of cardiovascular disease have yielded contradictory. Low, normal, 
and high levels of natural anticoagulants have been found in coronary artery 
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disease patients (60, 157, 282). Only a few studies have evaluated natural 
anticoagulants in diff erent phases of IS, with confl icting results (21, 248, 
249, 258, 285).
Factor V Leiden mutation (FVLm)
In 1993, Dahlbäck described a novel mechanism for familial thrombophilia 
(66). He identifi ed individuals with unexplained personal and familial 
histories of venous thromboembolism whose plasmas exhibited a poor 
response to APC. He called this phenomenon APC resistance (APCR). It 
was soon shown that the cause of APCR is most oft en a defect involving 
the substitution of arginine 506 with glutamine at nucleotide 1691 (Q506 
Leiden) in factor V cDNA (33). Th is is the site at which APC cleaves FVa, 
and this sequence alteration makes the mutant FVa molecule biochemically 
resistant to inactivation by the enzyme. Th e Arg506Gln substitution was 
found to be the cause in more than 90% of Dutch patients with APCR, but 
the mutation was also present in 2–4% of healthy Dutch control subjects (33). 
Th e Physicians’s Health Study has provided valuable data regarding FVLm 
as a risk factor for venous as well as arterial thrombosis. In a retrospective 
case-control study of 14 916 healthy men aged 40 years or more, with a mean 
follow-up period of 8.6 years, heterozygosity for FVLm was identifi ed in 12% 
of subjects with a fi rst episode of deep venous thrombosis or pulmonary 
embolism and in 6% of controls (211).
Th ere has been considerable interest in determining whether FVLm leads 
to an increased risk for arterial thrombosis. Large case-control studies (110, 
147, 154, 211, 252) have failed to fi nd an elevated frequency of FVLm among 
IS patients. Both case-control and prospective studies from the Copenhagen 
City Heart Study argue against an association between FVL and risk of adult 
IS. Th is conclusion is supported by the fi ndings of a meta-analysis (133).
However, some data indicate that FVLm may increase stroke occurrence 
in younger persons (18, 181). Moreover, several case reports have suggested 
that epistatic (gene-gene) interactions increase the risk of arterial thrombosis. 
An association between FVLm and migraine with aura has been proposed 
(63, 147), but no relationship between FVLm and the major IS risk factors 
has been found (154). Although it is not absolutely clear whether FVLm is a 
risk factor for IS itself, many young patients without an obvious cause and no 
common artheriosclerotic risk factors undergo testing for APCR and FVLm. 
Only a few studies exist on the clinical and radiological characteristics of 
IS patients with FVLm (115, 147, 154, 290). Almost all studies concerning 
the relationship between IS patients and FVLm were hampered by the small 
number of such patients. Since FVLm is found only in a small fraction 
of the population, most studies aimed at clarifying its role have not been 
conclusive.
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Fibrinolysis
Endothelial control of fi brin deposition is exerted via the fi brinolytic system. 
Th e main function of this system is to limit clot formation and degrade the 
fi brin deposits formed (Figure 6). Th e key enzyme responsible for doing 
this is plasmin. Plasmin cleaves fi brin into soluble fragments, but also 
has other important functions, such as increasing the activity of matrix 
metalloproteinases, resulting in enhancement of its proteolytic activity. 
Active plasmin is formed from plasminogen by the specifi c proteolytic 
action of tissue-type plasminogen activator (t-PA). Plasminogen can also 
be activated by urokinase-type plasminogen activator (u-PA), which is 
only marginally involved in clot lysis. Th e activities of both t-PA and u-PA 
are controlled by their specifi c inhibitors, plasminogen activator inhibitors 
(PAIs), mainly PAI-1, PAI-2, and PAI-3, PAI-1 being the most important 
(150). PAI-1 binds to fi brin and forms a stabile complex with t-PA or u-PA, 
inhibiting plasmin activation and fi brinolysis.
Figure 6. Plasmin-induced degradation of fi brin. Fibrin localizes plasminogen to the 
surface of the thrombus, where plasminogen is activated to plasmin by t-PA and u-PA. 
Th ese enzymes are regulated by PAI-1. Plasmin is responsible for the degradation 
of fi brin into fi brin degradation products (FDPs). Th e thin line indicates inhibition. 
Adapted from Lee: Arch Intern Med, Volume 163 (19), 2003, 2368–2392.
Endothelial cells of the normal arterial wall secrete t-PA, but little or no u-
PA. t-PA expression is particularly high in the brain (284). t-PA expression 
has been shown to respond to a few modulators, including endotoxin, 
bradykinin, endothelin, tumor necrosis factor (TNF), and thrombin (109). 
Expression of u-PA is highest in the kidney. u-PA provides pericellular 
proteolysis during cell migration and tissue remodeling and does not bind 
specifi cally to fi brin (162). PAI-1 is found in the circulation, largely in 
association with platelets. It is also secreted by endothelial cells (150). PAI-
1 expression is minimal in normal arteries (223). Infl ammatory cytokines, 
TNF, and lipoproteins are important factors in regulating vascular PAI-1 
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expression (109). Both t-PA and PAI-1 show circadian rhythm, with the 
highest PAI-1 activity and the lowest t-PA activity in the early morning (22). 
Th e morning hypercoagulability may partly be related to catecholamine and 
cortisol excretion (281).
Th e concept that impaired fi brinolysis is a risk factor for future vascular 
disease is strongly supported by numerous studies. PAI-1 activity is regulated 
by age; older populations tend to have lower PAI-1 levels (287). PAI-1 gene 
expression has been demonstrated to be increased in atherosclerotic plaque 
(223), and the increased local expression of PAI-1 at the site of atherosclerotic 
lesion formation could disturb the natural balance between coagulation, 
anticoagulation, and fi brinolysis, leading to a local prothrombotic condition 
(228). Several of the well-defi ned risk factors for atherosclerosis are 
associated with excessive PAI-1 activity (166, 282, 287). Two of the most 
common disorders leading to the development of atherosclerosis, AH and 
DM, alter PAI-1 and t-PA production unfavorably. A signifi cant correlation 
exists between plasma PAI-1 activity and the plasma renin-angiotensin/
system (46). Low t-PA levels have been reported in patients with AH (128). 
Plasma insulin has been suggested to be a major physiological regulator of 
PAI-1 activity and t-PA levels in plasma (132, 187). Recent data indicate 
that adipose tissue is an important source of PAI-1 (169). Two clinical 
studies demonstrated that patients with coronary syndrome had higher 
levels of t-PA:Ag and PAI-1 activity than controls (127, 224, 257). Activity 
of the fi brinolytic system in IS patients has also been investigated widely 
(53, 123, 130, 176), but the results are confl icting. Two prospective studies 
have shown that a high concentration of t-PA:Ag among healthy men was 
associated with an increased risk of future IS, especially thromboembolic 
stroke (212, 237). Elevated PAI-1 activity in stroke patients has also been 
reported (56, 164), and this might refl ect an endogenous predisposition to 
thrombogenesis (130).
Aft er coagulation is initiated, the reaction must be localized to the site 
of vascular damage and tightly regulated to maintain intravascular fl uidity. 
Th e fi brinolytic system removes fi brin-rich thrombi by plasmin-mediated 
proteolytical degradation of fi brin clots into soluble fragments. Plasmin-
induced degradation of fi brin is a stepwise process that results in the 
formation of many fragments (98). Fibrin fi brils are degraded to X-oligomers 
that consist of D- and E-fragments of fi brin in various combinations. Th e 
fragments decrease in size as the fi brinolytic process continues. Th e oligomers 
are further degraded to DDE-fragments and eventually to a D-dimer (79).
Elevated levels of D-dimer have been suggested to be a sensitive marker 
of intravascular thrombin or plasmin generation. It also may refl ect the 
extent and severity of underlying atherosclerosis (119, 159, 210). DeSouza 
et al. (72) found a signifi cant infl uence of age on plasma D-dimer levels. 
Prospective studies have reported elevated D-dimer levels in hypertensive 
patients (166, 276), but this observation was not confi rmed in a later study 
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(264). Th e correlation between D-dimer and dyslipidemia also seems to be 
weak (167). Th ere is some evidence that D-dimer correlates with diabetes 
mellitus as well as obesity (26). Modestly elevated circulating D-dimer values 
might refl ect minor increases in blood coagulation and turnover of cross-
linked intravascular fi brin (which is partly intra-arterial in origin), and thus, 
may be relevant to coronary heart disease (171). D-dimer has been associated 
with the risk of future coronary events (67) and the severity of coronary 
artery disease (250). Lassila et al. (156) found the severity of atherosclerosis 
to be associated with increased D-dimer levels in PAOD patients.
Some studies have demonstrated elevation of D-dimer levels in patients 
with acute IS (21, 259) and a correlation of D-dimer levels with stroke 
severity (32). With regard to stroke etiology, results have been inconsistent 
(64, 87, 103, 142, 183). Several previous studies have identifi ed D-dimer as an 
independent predictor of future stroke in healthy subjects (170, 236). Elevated 
D-dimer levels can predict progression of stroke (28), stroke mortality (87), 
and a high risk of recurrent stroke (248). Elevated D-dimer levels may refl ect 
an acute-phase response (28), an activation of coagulation secondary to 
tissue damage, or a complication in the course of stroke (infection or venous 
thromboembolism) (32).
Aims of the study36
Aims of the study
Serial changes in markers measuring coagulation, fi brinolysis, and 
vasoactivity in defi ned IS patients were investigated. Also of interest was to 
determine whether these markers could predict short- (3 months) and long-
term (3 years) outcome, including recurrent IS, in this patient population. We 
selected mildly or moderately aff ected IS patients to maximize the likelihood 
of survival over the study period and the possibility of follow-up, including 
both serial clinical and laboratory evaluation.
Specifi c aims were to shed light on the following questions regarding markers 
of coagulation, fi brinolysis, and vasoactivity:
1. How do markers measuring coagulation, fi brinolysis, and vasoactivity 
change in IS patients compared with control subjects free of vascular 
diseases (Studies I–IV)?
2. How do these markers vary over time following IS (Studies I–IV)?
3.  Are these markers associated with IS risk factors or stroke etiology 
(Studies I–IV)?
4. Do any changes in the markers measuring coagulation, fi brinolysis, and 
vasoactivity emerge as clinically useful in predicting the prognosis or 
recurrence of vascular events in IS patients (Studies I–IV)?
5. Is the presence of FVLm associated with specifi c clinical, laboratory, 
radiological, or other characteristics (Study V)?
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Subjects and methods
Subject characteristics
All study protocols were approved by the Ethics Committee of the Department 
of Neurology, University of Helsinki, and were carried out according to the 
principles of the Declaration of Helsinki. Informed consent was obtained 
from all participants. IS diagnosis was based on both clinical evidence and 
radiological fi ndings. Risk factors for IS were elicited from patient history, 
physical examination, previous hospital records, laboratory tests, and relatives’ 
reports in accordance with general criteria (104). All patients received standard 
stroke care and secondary prevention consistent with generally accepted 
recommendations (25) to minimize their risk of recurrence of thrombosis. 
Patients unable to give informed consent or refusing to participate, patients 
with a decreased level of consciousness, and patients suff ering severe strokes, 
thus likely to remain bedridden or to not survive survive the follow-up period, 
were excluded. Probability of survival was decided based on clinical fi ndings 
(NIHSS < 20) (220).
One hundred and two consecutive likely-to-survive patients with clinically 
and radiologically proven fi rst-ever IS admitted to the Department of 
Neurology, Helsinki University Central Hospital, were included (Studies I, 
II). Blood samples from one patient were missed before analysis in Study 
I (n=101). Similar numbers of sex- and age-matched control subjects, free 
from atherothrombotic or hematological disease, were selected from patients 
referred to the Outpatient Clinic of the Department of Neurology and from 
investigators’ relatives. None of the patients or controls had any concomitant 
medication or disease that could alter Hcy levels (126). In Studies III and IV, 
55 consecutive patients of the 102 patients described above were chosed based 
on their order of admission to hospital. Th e study protocol was similar to the 
one described above. An equal number of sex- and age-matched controls 
(n=55) were selected from the 102 control subjects described above. None of 
the control subjects received any medication that might aff ect coagulation or 
the fi brinolytic system.
In Study V, another 42 patients with clinically and radiologically confi rmed 
IS and documented FVLm admitted to the Department of Neurology, Helsinki 
University Central Hospital, were selected from 740 patients with IS without 
obvious etiology who were tested for FVLm. An equal number of FVLm-
negative IS patients matched for sex and age were selected from the same 
population. Th e decision for FVLm testing, based on the written protocol of 
our department, was made by the physicians responsible for the patients.
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Brain imaging and infarction classifi cation
All patients underwent CT or MRI of the brain. Infarct volumes were 
calculated using the following formula: AxBxC/2, as previously described 
(199). Classifi cation of IS was according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) criteria (13) (Studies I–IV). In Study V, the 
subtypes of ischemic stroke were categorized according to the Oxfordshire 
Community Stroke Project (OCSP) classifi cation (27). Th e presence and 
degree of leukoaraiosis (focal or diff use hypodensities in the periventricular 
or deep white matter, not involving the cortex) were evaluated with the 
leukoaraiosis Visual Rating Scale (37). Th e location and number of infarcts 
were determined by careful visual evaluations of brain images using either 
CT or MRI. Th e patients were classifi ed into four subgroups according to 
radiological features. Group 1 had small-vessel occlusion (one or more 
hemispheric or brainstem infarctions with  diameter < 1.5 cm), Group 
2 large-vessel occlusion (cortical/cerebellar/brainstem infarctions with 
diameter ≥ 1.5 cm), Group 3 subcortical hemispheric infarctions, and Group 
4 mixed vascular pathology (246).
Assessment of neurological status and outcome
Patients underwent neurological examination on admission and at 1 week 
(7 ± 1 days), 1 month (30 ± 3 days), and 3 months (90 ± 7 days). National 
Institute of Health Stroke Score (NIHSS), Scandinavian Stroke Scale (SSS), 
and Glasgow Coma Scale (GCS) were performed at each time point, and the 
Barthel Index (BI), Modifi ed Rankin Score (mRS), and Mini-Mental State 
Examination (MMSE) once at 3 months. A 3-year follow-up was performed 
by telephone, and in case of IS recurrence, hospital records were reviewed 
(Studies I–V). No patients were lost to follow-up, but two patients died in the 
acute stage of stroke because of a large brain infarction. Both FVLm-positive 
and FVLm-negative IS patients underwent neurological examination on 
admission, at discharge from the hospital, and at 3 months. NIHSS and SSS 
were performed at each time point, and BI and mRS at 3 months and at the 
end of the follow-up period (Study V). 
Blood sampling
Fasting venous blood samples were collected without venous stasis from an 
antecubital vein via a 19-gauge scalp needle at the time of the neurological 
examinations on admission (within 2 days of stroke) and at 1 week (7 ± 1 
days), 1 month (30 ± 3 days), and 3 months (90 ± 7 days). Sex- and age-
matched controls underwent blood sampling once. All blood samples were 
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collected between 8 and 10 a.m. to eliminate possible circadian eff ects. Aft er 
discharging the fi rst 2–3 mL, blood was collected into a sterile 3-mL vacuum 
tube containing 10 mL sterile 3.2% sodium citrate (Venoject, Terumo Europe 
N.V., Leuven, Belgium). Plasma was separated by centrifugation immediately 
at 2 000g for 20 min at 4°C. Plasma was quickly frozen and stored at –70°C 
until analyzed.
Plasma ET-1 (pg/mL) concentration was quantifi ed using a commercially 
available sandwich-enzyme immunoassay kit (R and D System) aft er 
extraction (244) (Study I).
Plasma Hcy was measured using a standard competitive immunoassay 
method (Immulite 2000, Diagnostic Product Corporation, Los Angeles, 
California, USA). Serum B12 vitamin, serum folic acid, and CRP 
concentrations on admission were determined with standard laboratory 
methods (Study II).
AT and PC activities were measured with chromogenic assays (Coamatic 
AT 400 and Coamatic Protein C, Chromogenix AB, Mölndal, Sweden) on 
an automated coagulameter (Th rombolyzer, Behnk Elektronik GMBH & 
Co., Norderstedt, Germany). Free PS activity was measured on the same 
instrument aft er polyethylene glycol treatment with an immunological 
method (Liatest Protein S, Diagnostica Stago, Asnieres, France). Percentage 
(of activity/amount of a reference plasma or pooled normal plasma) is 
an established way to express the amount of clotting factors in plasma 
samples. AT and PC levels are expressed as percentage of activity of normal 
reference plasma. PS levels were measured as free PS antigen, and the results 
are expressed as percentage of free PS antigen in pooled normal plasma 
(Study III).
In Study IV, F1+2 (nmol/L) and TAT (mg/L) concentrations were measured 
with commercial reagents (Enzygnost F1+2 micro and Enzygnost TAT 
micro, Behringwerke AG, Marburg, Germany). t-PA levels (ng/mL) were 
measured as antigen concentration with a commercially available enzyme-
linked immunosorbent assay (ELISA) method (Coaliza t-PA, Chromogenix 
AB) according to the manufacturer’s instructions. PAI-1 activity (AU/mL) 
was determined with a chromogenic method (Coatest PAI; Chromogenix 
AB, Mölndal, Sweden) according to the manufacturer’s instructions. D-dimer 
concentration was measured with a commercial method (Asserachrom D-
Di, Diagnostica Stago, Asnieres, France), and the results are expressed as 
fi brinogen equivalent units (FEU, mikrog/L).
In Study V, all patients were tested for both APCR and FVL. Th e laboratory 
technique for testing APCR was to defi ne the ratio between activated partial 
thromboplastin time before and aft er adding APC to the sample. Th e cut-
off  value was 2.0. We used minisequencing complementary DNA to detect 
the FVL mutation, as described by Bertina et al. (33). In addition to the 
APCR and FVLm tests, all patients were screened for the presence of any 
concomitant thrombophilic coagulation disorder, including defi ciencies in 
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AT, PC, and PS, presence of lupus anticoagulant or cardiolipin antibodies, 
and plasma homocysteine concentration according to standard laboratory 
methods. Blood glucose and serum lipid levels were determined in serum 
3 months aft er stroke with standard laboratory methods (Studies I–V).
Statistical methods
Th e main results are given as median and mean ± SD. Because of positively 
skewed distributions, the comparisons were made with logarithmically 
transformed data. Th e distributions of the parameters were plotted and 
tested with Shapiro-Wilk’s test. Th e data for hemostatic markers for patients 
at diff erent time points and for controls were compared by Wilcoxon’s 
matched-pairs signed-rank sum test and corrected for multiple comparison 
(Bonferroni). Patients with and without a particular IS risk factor as well 
as patients with and without a recurrent ischemic stroke were compared 
with Mann-Whitney U-test for continuous variables, and chi-square test or 
Fisher’s test, as appropriate, for dichotomous variables. Correlation between 
two continuous variables was calculated with Spearman’s rank correlation 
coeffi  cient. Stratifi ed by diff erent etiologies of stroke, the parameters were 
studied with Kruskal-Wallis analysis of variance. Correlations between 
hemostatic markers and neurological scores were calculated by Spearman’s 
rank correlation coeffi  cient. Th e predictive value for recurrence or outcome 
was determined with fi xed and stepwise logistic regression. A two-tailed 
p-value < 0.05 was considered signifi cant.
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Results
General information about IS patients
Clinical and demographic features of study participants (Studies I–IV) are 
shown in Table 2. No patients had a recurrent IS during the fi rst 3 months 
aft er stroke (Studies I–IV). Th irty recurrent IS occurred in 29 patients 
(Studies I, II), and 12 IS occurred in 12 patients (Studies III, IV) during the 
3-year follow-up.
Table 2. Clinical and demographic features of study participants.




Studies III, IV 
(n=55)
Sex (male/female) 64/37 65/37 40/15
Age (years) 64.3 ± 12.3 63.1 ± 12.2 60.2 ± 11.4
Body mass index (kg/m2)   < 27/≥ 27 52/49 53/49 26/29
Hypertension                        yes/no 53/48 54/48 27/28
Diabetes mellitus                  yes/no 20/81 19/83 7/48
Smoking                                yes/no 54/47 53/49 34/21
Cholesterol (mmol/L)         < 6.0/≥ 6.0 63/38 63/39 32/23
Triglycerides (mmol/L)      < 1.75/≥ 1.75 72/29 73/29 37/18
LDL cholesterol (mmol/L) < 4.0/≥ 4.0 58/43 59/43 27/28
HDL cholesterol (mmol/L) < 1.12/≥ 1.12 49/52 50/52 24/21
Sleep apnea                           yes/no 29/72 28/74 21/34
TOAST group
      large-artery atherosclerosis
      cardioembolism
      small-artery occlusion
      stroke of other determined cause

















Of study patients, 27–36% were on anticoagulation therapy (Table 3).











anticoagulation    
ongoing/no 42/59 33/68 29/72 27/74
Study II (n=102)
anticoagulation    
ongoing/no 42/60 33/69 29/73 27/75
Studies III, IV (n=55)
anticoagulation    
ongoing/no 20/35 18/37 16/39 15/40
Clinical and demographic features of Study V participants are presented 
in Table 4. We observed 253 patient-years among IS patients with FVLm 
and 262 patient-years among patients without FVLm. Th e mean follow-up 
period was 6.0 ± 2.9 years for FVLm-positive patients and 6.2 ± 2.8 years 
for FVLm-negative patients. No patients from either group had recurrent 
IS during the fi rst 3 months aft er stroke, but 14 FVLm-positive patients and 
11 FVLm-negative patients had a recurrent thromboembolic event during 
the follow-up (6.0 ± 2.9 years for FVLm-positive patients and 6.2 ± 2.8 years 
for FVLm-negative patients).
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Age (years) 49.5 (50.7±10.5) 49.0 (50.1±10.6)
Sex (male/female) 23/19 23/19
Hypertension 22 23
Diabetes mellitus type I 1 1
Diabetes mellitus type II 2 2
History of myocardial infarction 2 1
Body mass index (kg/m2) 24.6 (25.1±3.1) 24.0 (24.8±3.1)
Smoking 19 16
Heavy alcohol > 200 g/week 1 2
Paroxysmal atrial fi brillation 4 2
Peripheral vascular disease 4* 0
Coronary heart disease 6 3
Previous transient ischemic attack 10 8
Previous ischemic stroke 5 2
Previous venous thromboembolism 4 1
Migraine with aura 12 13
Family history of venous thromboembolism 4* 0
Family history of coronary disease 19* 8
Oral contraceptive use 2 0
Hormonal replacement therapy 4* 0
Total cholesterol level (mmol/L) 5.3 (5.6±1.4) 4.9 (5.0±1.1)
Triglyceride level (mmol/L) 1.5 (1.9±1.8) 1.3 (1.4±0.8)
HDL cholesterol level (mmol/L) 1.2 (1.3±0.4) 1.3 (1.3±0.4)
LDL cholesterol level (mmol/L) 3.1 (3.5±1.2) 3.0 (3.1±1.0)
All values are median (mean ± SD). * p < 0.05
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Markers measuring coagulation, fi brinolysis, 
and vasoactivity in patient subgroups
Table 5. Markers measuring coagulation, fi brinolysis, and vasoactivity in diff erent 
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0.4 (0.6±0.7) * 
1.4 (1.7±0.8)
TAT (mg/L)
   All patients






1.7 (2.1±1.1) * 
4.3 (6.0±6.2)
2.5 (3.8±4.5) * 
3.6 (5.0±5.2)
t-PA:Ag (ng/mL)
   All patients
   AC patients
7.7 (8.8±4.2)
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AC, anticoagulated. All values are median (mean ± SD). * p < 0.05
ET-1 (Study I)
ET-1 levels in IS patients did not signifi cantly (p > 0.05) diff er from those 
of controls at any time point (Table 5). Patients receiving warfarin had 
signifi cantly higher ET-1 levels at 1 and 3 months than patients receiving 
antiplatelet drugs (p = 0.009 and 0.03, respectively) (Table 5).
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Among the factors that have the potential to aff ect ET-1 levels, including 
gender, age, BMI, AH, DM, dyslipidemia, smoking, and sleep apnea, only 
BMI and HDL-cholesterol showed a positive correlation with ET-1 levels 
(p < 0.05).
Hcy (Study II)
Hcy levels were signifi cantly lower in stroke patients than in controls (p < 
0.001) on admission, and were similar at later time points, as they increased 
at 1 week and remained at the same level up to 3 months (Table 5). Hcy 
levels among patients receiving anticoagulant treatment did not diff er from 
nonanticoagulated patients (Table 5).
Th ere were no diff erences between patients and control subjects in serum 
B12 (384.3 ± 176.3 ng/L vs. 379.8 ± 166.1 ng/L, p = 0.6) or folic acid levels 
(14.7 ± 5.8 nmol/L vs. 17.3 ± 10.0 nmol/L, p = 0.5). Serum B12 and folic 
acid levels showed a signifi cant inverse correlation with Hcy levels in both 
groups (p < 0.01). Presence or absence of such IS risk factors as sex, BMI, AH, 
DM, dyslipidemia, smoking, and sleep apnea did not aff ect Hcy levels. Age 
showed a positive correlation with Hcy levels at all time points (p < 0.01) in 
stroke patients, but not in controls. Mean CRP concentration on admission 
was 6.0 ± 5.2 mg/L. No correlation was identifi ed between admission CRP 
concentration and Hcy levels at any time point. 
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Figure 7.  PAI-1 activity at various stage of IS. IS patients (◆) and controls (■). 
Standard deviation indicated by whiskers.
Plasma levels of D-dimer of patients at 1 week and 1 month were signifi cantly 
higher than those of controls (p < 0.005 and p < 0.05, respectively) 
(Figure 8).
Figure 8. D-dimer levels at various stage of IS. IS patients (◆) and controls (■). 
Standard deviation indicated by whiskers.
Markers measuring activity of coagulation and fi brinolysis 
(F1+2, TAT, t-PA:Ag, PAI-1, and D-dimer, Study III)
F1+2, TAT, and t-PA:Ag levels of patients did not diff er from those of controls 
at any time point (Table 5). PAI-1 activity of patients was signifi cantly higher 
than that of controls on admission (p = 0.02) and at 3 months (p = 0.003), 
but not at 1 week or at 1 month (Figure 7).
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Patients on anticoagulant treatment had higher t-PA:Ag and PAI-1 levels on 
admission than nonanticoagulated patients (p < 0.01), but not at later time 
points. Patients receiving anticoagulant treatment had lower F1+2, TAT, and 
D-dimer levels at 1 month and 3 months than nonanticoagulated patients 
(p < 0.005), but in acute and subacute phases of stroke, no diff erence was 
observed (Table 5).
Among all recorded factors that might correlate with coagulation and 
fi brinolysis markers (age, sex, DM, AH, serum total cholesterol, serum 
triglyceride, LDL-cholesterol, BMI, sleep apnea, and smoking), age showed 
an inverse correlation with PAI-1 activity on admission and at 1 week, 1 
month, and 3 months (p = 0.05, 0.1, 0.04, and 0.06, respectively), and BMI 
showed a positive correlation with PAI-1 activity only at 3 months (p = 
0.04). D-dimer levels were not correlated with the presence or absence of 
any risk factors for IS other than age on admission and at 1 week, 1 month, 
and 3 months (p-values of < 0.005, < 0.01, < 0.01, and < 0.001, respectively). 
F1+2, TAT, and t-PA:Ag levels showed no correlation with potential stroke 
risk factors.
Natural anticoagulants (AT, PC, and PS, Study IV)
AT levels were signifi cantly lower at all time points in IS patients than in 
controls (Figure 9). 
Figure 9. AT levels at various stage of IS. IS patients (◆) and controls (■). Standard 
deviation indicated by whiskers.
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In IS patients, PC level was signifi cantly higher on admission but not diff erent 
at later time points from control subjects (Figure 10).
Figure 10. PC levels at various stage of IS. IS patients (◆) and controls (■). Standard 
deviation indicated by whiskers.
PS level was normal on admission but signifi cantly lower at later time 
points over 3-month period in IS patients compared with control subjects 
(Figure 11).
Figure 11. PS levels at various stage of IS. IS patients (◆) and controls (■). Standard 
deviation indicated by whiskers.
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Patients receiving anticoagulant treatment had signifi cantly lower AT levels 
on admission (p = 0.01) as well as lower PC and PS levels at 1 week, 1 month, 
and 3 months than patients using antiplatelet drugs (Table 5).
Age showed a signifi cant positive correlation with AT levels at 1 week and 
1 month (p < 0.001 and p < 0.05, respectively). PC level was signifi cantly 
correlated with LDL-cholesterol on admission only (p < 0.05). Females had 
lower PS levels on admission and at 3 months than males. PS levels were 
higher in patients with sleep apnea on admission and at 1 week aft er stroke 
(p < 0.05). Presence or absence of the stroke risk factors of obesity, DM, 
smoking, and AH did not aff ect natural coagulant levels (p > 0.05 for all).
FVLm (Study V)
Baseline characteristics of FVLm-positive and FVLm-negative IS patients 
are given in Table 4. A few diff erences were seen; FVLm-positive patients 
more oft en received hormonal replacement therapy (4 vs 0, p < 0.05), had 
a higher prevalence of peripheral vascular disease (4 vs 0, p < 0.05), and 
more frequently had family histories of coronary disease (19 vs 8, p < 0.05) 
and venous thromboembolism (4 vs 0, p < 0.05) than  FVLm-negative 
patients.
Markers measuring coagulation, fi brinolysis, and 
vasoactivity and stroke etiology, severity, outcome, 
and recurrence
Th e neurological scores of Studies I–IV are summarized in Table 6. 
Table 6. Neurological scores of IS patients at diff erent time points (Studies I–IV).
Neurological score Admission 1 week 1 month 3 months
National Institute of Health Stroke Score
                Studies I, II (n = 102)










                Studies I, II (n = 102)










                Studies I, II (n = 102)




Modifi ed Rankin Scale
               Studies I, II (n = 102)





              Studies I, II ( n = 102)




All values are median (mean ± SD).
Results50
No correlation was found between ET-1 levels and stroke severity or outcome. 
A negative correlation was present between Hcy levels at all time points and 
MMSE at 3 months (p < 0.01). F1+2, TAT, and t-PA:Ag levels, PAI-1 activity, 
and PC and PS levels showed no correlation with stroke severity or outcome. 
AT levels on admission were positively correlated with disability and stroke 
severity (BI and NIHSS at 3 months, p = 0.03 and p = 0.04, respectively). 
D-dimer levels on admission and at 1 week were positively correlated with 
outcome and disability (mRS and BI at 3 months, p < 0.05).
Th e neurological scores of Study V are summarized in Table 7. 
Table 7. Neurological scores of FVLm-positive and FVLm-negative IS patients at 
diff erent time point (Study V).





Scandinavian Stroke Scale 55.5 (52.7 ± 7.2) 52.5 (49.5 ± 10.3)
National Institute of Health Stroke Score 3.0 (3.6 ± 3.1) 4.0 (4.9 ± 3.8)
at discharge from hospital
Scandinavian Stroke Scale 58.0 (56.3 ± 3.8) 56.0 (54.5 ± 5.0)
National Institute of Health Stroke Score 1.0 (1.7 ± 2.1) 2.0 (2.2 ± 2.3)
at 3 months
Scandinavian Stroke Scale 58.0 (57.2 ± 2.0) 58.0 (56.6 ± 2.9)
National Institute of Health Stroke Score 0 (1 ± 1.7) 0 (0.9 ± 1.6)
Barthel Index 100 (99.0 ± 6.2) 100 (99.4 ± 2.3)
Modifi ed Rankin Scale 1 (0.7 ± 0.8) 1 (1.3 ± 2.3)
at end of follow-up
Barthel Index 100 (98.7 ± 6.6) 100 (99.9 ± 0.8)
Modifi ed Rankin Scale 0.5 (0.6 ± 0.8) 1 (0.9 ± 0.8)
All values are median (mean ± SD).
No diff erences were observed in stroke severity, stroke outcome, or disability 
between FVLm-positive and FVLm-negative IS patients (p > 0.05).
Of all markers measuring coagulation, fi brinolysis, and vasoactivity 
(Studies I–IV), only F1+2 levels at 3 months showed a positive correlation 
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with recurrence of thromboembolic events (p = 0.02). Etiology of brain 
infarction was not associated with marker levels at any time of measurement 
(Studies I–IV). Recurrence rate of thromboembolic events showed no 
correlation with FVLm positivity (Study V). Th e annual recurrence rate in 
FVLm-positive and FVLm-negative groups showed no association with the 
treatment regimen (aspirin/warfarin, p > 0.05).
Brain imaging
In Study II, the mean infarct volume was 16.0 ± 27.5 cm3. No correlation 
was found between Hcy levels and size of brain infarction.
In comparing FVLm-positive and FVLm-negative patients (Study V), 
no diff erences were observed in stroke subtype, infarction location, and 
size, or in presence/degree of leukoaraiosis. In the FVLm-positive group, 
21 patients had more than one infarction (2 or more) compared with two 
patients in the FVLm-negative group (p < 0.02) (Tables 8, 9).
Table 8. Brain imaging characteristics of FVLm-positive and FVLm-negative IS 






Total Anterior Circulation Infarction (TACI) 0 0
Lacunar Infarction (LACI) 15 14
Partial Anterior Circulation Infarction (PACI) 13 10
Posterior Circulation Infarction (POCI) 14 13
Presence of leukoaraiosis: number (%) 11 (26) 18 (43)
Level of leukoaraiosis
                0 31 24
                1 6 10
                2 4 8
                3 1 0
                4 0 0
Age of patients with leukoaraiosis (years) 55.0 (60.0 ± 9.6) 49.0 (50.8 ± 8.7)
OCSP, Oxfordshire Community Stroke Project.  All p-values > 0.05.
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Table 9. Brain imaging characteristics of FVLm-positive and FVLm-negative IS 
patients.




Group 1: small-vessel disease 18 13
Group 2: large-vessel occlusion 10 14
Group 3: subcortical hemispheric infarctions 6 9
Group 4: mixed vascular pathology 7 6
Multiple infarctions (2 or more) 21 2
No visible infarction 1 0
All p-values > 0.05, except for multiple infarctions (p < 0.02).
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Discussion
Th is was a follow-up case-control study of IS patients, with serial 
measurements of markers of coagulation, fi brinolysis, and vasoactivity 
and repeated neurological examinations. Th e purpose was to investigate 
serial changes in these markers and to determine whether the markers 
could predict short-term (3 months) and long-term (3 years) outcome, 
including recurrent IS. We selected patients with mild or moderate IS to 
maximize the likelihood of survival over the study period and to allow 
repeated neurological evaluations and a long-term follow-up. We had a 
special interest in serial measurements of several coagulation-associated 
markers, as previous studies have typically included one or a few sets of 
markers.
Spesifi c objectives were to elucidate (1) whether repeated measurements 
of markers assessing coagulation, fi brinolysis, and vasoactivity disclose any 
patterns that might help in evaluating IS patients, including early diagnosis 
of stroke subtypes, in estimating prognosis and risk of recurrence, and in 
selecting a treatment for secondary prevention of stroke, and (2) whether 
patients with FVLm and IS share common characteristics that may arouse 
suspicion of FVLm on clinical grounds and indicate the test to verify or 
exclude the presence of FVLm.
Repeated measurements of ET-1 levels did not disclose information that 
could foster the diagnostic evaluation of IS patients (I). Plasma Hcy levels 
were signifi cantly lower in IS patients than in controls in the acute stage, 
increasing and remaining stable during the convalescent period (II). Our 
3-year follow-up examination showed that F1+2 level at 3 months aft er 
stroke had a positive correlation with recurrence of IS and may be used as 
a predictive marker of subsequent cerebral events (III). D-dimer and AT 
levels on admission and D-dimer level at 1 week were positively correlated 
with stroke outcome and disability (III, IV). IS patients with heterozygous 
FVLm more oft en had a positive family history of thrombosis, a higher 
prevalence of peripheral vascular disease, and multiple infarctions in brain 
images, most of which were ‘silent infarcts’ (V).
Th is study has certain limitations. Th e fi rst blood samples were mostly 
taken between 24 and 48 h aft er stroke, and consequently, a hyperacute peak 
in fi brinolytic or coagulation activity could have been missed. Th e study 
population was male-dominant. Our patients were in better condition than 
the average stroke patient to maximize the likelihood of their survival until 
the end of follow-up. Severely ill stroke patients are frequently bedridden and 
incur such confounding factors as fever, infections, and DVT, which aff ect 
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the markers of coagulation, fi brinolysis, and vasoactivity. Th e most serious 
limitation in our study was that 27–36% of patients used anticoagulant 
therapy. Th is treatment has an eff ect on markers of coagulation and 
fi brinolysis, thus infl uencing study results. Th e decision for FVLm testing 
was reached by physicians responsible for the patients; possibly, severely 
aff ected stroke patients and patients who died early were not tested for 
FVLm. For this reason, our study cannot rule out whether FVLm-positive 
patients had a poor prognosis. In addition, only some of the patients in Study 
V were evaluated to exclude patent foramen ovale (PFO).
Changes in markers measuring coagulation, fi brinolysis, 
and vasoactivity over time
ET-1 (Study I)
ET-1 could be involved in the pathogenesis of IS because it has a strong 
and long-lasting vasoconstrictor eff ect. Vasoconstriction due to ET-1 in 
atherosclerotic arteries is signifi cantly more pronounced than in normal 
vessels (41). Recent studies have demonstrated a rapid increase in circulating 
plasma ET-1 levels in the acute phase (20, 23, 86) as well as in the chronic phase 
(23) of IS. Normal levels of ET-1 have also been reported (111). Endothelial 
cells release ET-1 in response to various stimuli such as hypoxia (216), 
transforming growth factor (151), and thrombin (286). Experimentally, the 
depth of injury to the vessel wall was found to be an important determinant 
of the amount of thrombus formation, and ET-1 levels may be higher in 
extensive brain tissue necrosis (86).
We expected plasma ET-1 levels in IS patients to be higher than in controls, 
although this was not the case. Th is may be due to the following factors. 
Only patients with mild to moderate IS were included in our study because 
of their anticipated longer survival. Th us, most of our patients had small- 
to medium-sized infarctions and were in better condition than the average 
stroke patient. In addition, increased local production of ET-1 may not be 
correctly detected in peripheral blood because ET-1 is a local regulating 
factor and is higher at the interface of the endothelium than in plasma (161). 
Lampl et al. (155) reported an elevated ET-1 in CSF among IS patients, 
whereas plasma values did not show any signifi cant changes. Measurement 
from the CSF during the hyperacute phase may yield more accurate results. 
Plasma ET-1 levels increase within 60–150 min of thrombotic occlusion 
(95). In our patients, the fi rst blood samples were usually taken between 
24 and 48 h aft er stroke; thus, we may have missed the elevation of ET-1 at 
the hyperacute phase. Regardless of these limitations, our study does not 
provide evidence of a major role for ET-1 in IS.
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Hcy (Study II)
Although a rise of plasma Hcy levels exceeding 15 mmol/L is at present 
considered an independent risk factor for vascular disease, including IS 
(16), it remains uncertain whether Hcy is a causal risk factor for stroke or 
is a marker of other stroke-associated factors (4, 39).
Plasma Hcy levels were signifi cantly lower in our IS patients than in 
controls on admission, but increased in the subacute stage and remained 
stable during the convalescent period. Hcy levels were similar to those of 
control subjects aft er the acute stroke stage. Lindgren et al. (163) found that 
in 17 patients re-examined in the convalescent phase of IS, plasma Hcy values 
were signifi cantly higher than in the acute phase. By contrast, plasma Hcy 
levels did not change signifi cantly over time in the 20 re-examined control 
subjects. Meiklejohn et al. (188) showed that plasma Hcy levels aft er recent 
atherothrombotic stroke did not diff er from control subjects. However, 
plasma Hcy levels increased signifi cantly in the convalescent period and were 
then signifi cantly higher than in control subjects (188). In a recent study, 
Hcy levels were shown to increase during the acute period aft er stroke (122). 
We do not know whether this acute decrease in Hcy levels upon onset of IS 
is a protective reaction of the human body aimed at limiting brain injury 
or is solely a nonspecifi c acute-phase reaction (81). Plasma Hcy levels on 
admission could refl ect a premorbid state, with environmental factors, such 
as low dietary folate or several widely used drugs (e.g. statins, metformin, 
insulin), altering Hcy levels (77). Genetic factors may also play a role in 
explaining the study results. Racial and geographic diff erences are known 
to exist in the atherosclerotic process in cerebral arteries (238). Studies from 
African white and black populations have shown a signifi cant diff erence in 
favor of the black population in Hcy levels, highlighting the importance of 
genetic factors (269, 277). Th e lack of association between Hcy and IS in 
our study and similar results in previous studies of the Finnish population 
(19, 138) suggest a role for genetic factors and a low overall prevalence of 
hyperhomocysteinemia in Finland. 
Fibrinolysis and coagulation markers 
(F1+2, TAT, t-PA:Ag, PAI-1, D-dimer, Study III)
F1+2, TAT, and t-PA:Ag levels were not signifi cantly diff erent from those of 
control subjects at any time point. Th ese fi ndings are at odds with several 
earlier studies (21, 103, 164, 249), probably due to patient selection; our 
patients had milder than average strokes, suff ering small- to medium-
sized infarcts. Th e results may be diff erent in severely ill stroke patients 
who have large infarcts, probably a larger mass of clot material, and more 
frequently suff er from other confounding factors such as fever, infections, 
and a depressed level of consciousness, and thus, are more prone to other 
thromboembolic complications. PAI-1 activity was increased on admission 
and at 3 months, but normal at 1 week and at 1 month aft er IS. Th e results 
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confi rm previous fi ndings of increased PAI-1 activity both in the acute phase 
and in the convalescent phase aft er stroke (21, 164). Increased PAI-1 activity 
in stroke patients may be associated with an acute-phase reaction (131) or 
it might refl ect an endogenous predisposition to thrombogenesis (130). 
Normalized post-stroke PAI-1 levels at 1 week and 1 month may suggest 
enhanced in fi brinolytic activity in these patients, possible also being due to 
use of antithrombotic agents, vigorous physical rehabilitation, cessation of 
smoking, hospital diet, better care for diabetes and hypertension in hospital, 
or other yet unknown factors. High PAI-1 activity at 3 months post-stroke 
may be associated with a rebound hypercoagulable state or may refl ect a 
high rate of synthesis and release from atherosclerotic vessels (227).
We found D-dimer levels to be signifi cantly higher in the subacute phase of 
IS (1 week and 1 month), but not in the chronic phase, which is in accordance 
with previous reports (21, 123). Elevated D-dimer levels may refl ect an acute-
phase response (28), an activation of coagulation secondary to tissue damage, or 
a complication in the course of stroke (infection or venous thromboembolism) 
(32). Elevated D-dimer levels could also be caused by continuous formation 
and subsequent lysis of fi brin (93). Anticoagulant treatment can normalize 
D-dimer levels in the convalescent phase of stroke (198).
Natural anticoagulants (AT, PC, and PS, Study IV)
A distinct pattern of natural anticoagulant activity is present in IS; while 
AT level remains signifi cantly decreased at all time points aft er stroke, PC 
level is increased on admission, becoming normalized later. PS level in turn 
is normal in the acute phase of stroke and decreases later.
In patients with IS, AT level was previously reported as either decreased 
(21) or normal (285). Takano et al. (249) showed that AT activity was 
signifi cantly lower at the time of admission in cardioembolic IS patients 
compared with controls. Th e low AT levels probably refl ect an increased 
consumption of active AT in the acute phase. Because unfractionated heparin 
(UFH) indirectly inhibits thrombin through an antithrombin-dependent 
mechanism, frequent use of UFH in our patients in the acute stage of IS 
could also explain this fi nding (192). Our patients had lower AT levels up to 3 
months aft er stroke, suggesting that the coagulation system had not returned 
to normal even then, whereas in two previous studies (249, 259), the AT level 
increased with time and normalized in a few weeks following stroke. Th is is 
likely because of a chronic activation of the fi brinolysis system.
PC level has been found to be low (248) or normal (285) during the acute 
phase and normal in the convalescent phase of IS (285). In our study, we 
observed a signifi cantly high PC level on admission and normal PC levels 
thereaft er. Th e variation in results between other studies and ours most 
likely refl ects diff erences in patient selection since in the previous studies, 
the lowest PC levels were observed in the most severely ill patients, and such 
patients were excluded from our study. Th e normalized PC levels at later 
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time points may also refl ect the eff ect of oral anticoagulant therapy (153).
We found PS levels to be signifi cantly low in the subacute and chronic 
phases of IS but not in the acute phase. Th is is in agreement with results of 
some studies (21, 136), while another study (24) reported low free PS levels in 
8 of 43 patients with IS in an acute setting. Th e varying and partly confl icting 
results of diff erent studies may be due to diff erent patient population 
characteristics, laboratory methods, time points of examination, stroke 
classifi cations used, or whether warfarin treatment was administered.
Markers measuring coagulation, fi brinolysis, 
and vasoactivity and stroke risk factors (Studies I–V)
Th e relationship between markers of coagulation, fi brinolysis, and 
vasoactivity and several IS risk factors has previously been investigated, 
with confl icting results (16, 166, 204, 218, 226, 287). We found a signifi cant 
correlation between these markers and such major stroke risk factors as 
age (Hcy, AT, PAI-1, and D-dimer), sex (PS), BMI (ET-1, PAI-1), and LDL-
cholesterol (AT, PC), whereas AH, DM, dyslipidemia, smoking, and sleep 
apnea did not aff ect hemostatic markers. In general, patient selection, type 
and duration of concomitant diseases, regimen and effi  ciency of treatment, 
existence of complications, and some other confounding factors may have 
had an infl uence on our results. Th e results of previous studies have been 
highly variable in the literature, and therefore, allow no fi rm conclusions 
to be drawn.
Our results, in agreement with those of Lalouschek et al. (154), showed 
that no signifi cant correlation exists between the presence of FVLm and the 
major stroke risk factors. Moreover, we found no association between classical 
migraine and FVLm positivity in IS patients, which is again consistent with 
a previous report (124). We did observe a higher prevalence of peripheral 
vascular disease among FVLm-positive patients, comparable to the fi ndings 
of Sykes et al. (245). In accordance with previous studies (108, 265), carrier 
status for FVLm was associated with family history of thrombosis. Since 
FVLm has been established as an autosomal dominant trait, this fi nding is 
quite plausible. However, a positive family history of thrombosis was found 
in only a minority of our patients, thus, its predictive value was only modest. 
Positive family histories of venous thrombosis and cardiovascular events 
were not present among the same patients. Interestingly, FVLm carriers 
did not suff er from early venous thrombosis more oft en than those without 
FVLm, contrary to earlier reports (194, 225). FVLm positivity in IS patients 
was not associated with defi ciencies in natural anticoagulants. Dahlbäck et al. 
(65) found no signifi cant link between the presence of FVLm and cardiolipin 
IgG antibodies or lupus anticoagulant; our results are consistent with this.
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Markers measuring coagulation, fi brinolysis 
and vasoactivity, and stroke etiology, severity, 
outcome, and recurrence rate (Studies I-IV)
Pathogenetic mechanisms may diff er in various subtypes of IS. Consequently, 
some investigators have suggested that coagulation and fi brinolytic 
parameters may distinguish various stroke subtypes. Our results did not 
indicate any relationship between plasma ET-1 levels (Study I) and cause 
of stroke, which is in agreement with data reported by Estrada et al. (86). 
Previous studies (20, 23, 155) have described signifi cantly higher plasma ET-
1 levels in large cortical and cardiogenic infarctions that could be explained 
by anticoagulant use, as also the case in our study.
High Hcy levels have been associated with subtypes of IS caused by large-
artery and small-artery disease (82, 288) as well as cardiogenic disease (233). 
In Study II, Hcy levels did not vary with the etiology of IS, supporting the 
fi ndings of Bushnell et al. (50).
Concerning natural anticoagulants (Study III), we found that PC and PS 
levels were signifi cantly lower in patients with cardioembolic infarction. PC 
and PS levels are lowered by warfarin treatment (248), which is the most 
likely explanation for this fi nding. In Study IV, we found no signifi cant 
relationship between the etiology of brain infarction and AT, F1+2, TAT, 
t-PA:Ag, PAI-1, or D-dimer levels. Th e discrepancy between this fi nding 
and previous results (21, 87, 89, 96, 142, 248) can be explained in several 
ways. Th e small number of patients in each stroke subgroup hampers the 
reliability of results. In addition, IS has been classifi ed according to diff erent 
criteria in earlier studies. Furthermore, treatment regimen (antithrombotic 
vs. anticoagulant treatment) will have an eff ect on the levels of the markers 
of coagulation and fi brinolysis.
We were unable to reveal an association between the subtypes of IS and 
the presence of FVLm (Study V), similar to previous studies (115, 290).
We hypothesized that activation of coagulation and fi brinolysis could be 
an important cause in severely aff ected stroke patients because of disturbed 
endothelial function, large masses of thrombi, and large tissue necrosis 
in the brain. In Study II, elevated Hcy levels showed a signifi cant inverse 
correlation with MMSE, in agreement with previous reports (230). Th is 
fi nding is likely an epiphenomenon, refl ecting the parallel infl uence of aging 
on both cognitive performance and Hcy levels, in opposite directions, rather 
than an independent causal eff ect of Hcy levels on cognition.
AT levels (Study III) were signifi cantly correlated with stroke severity and 
outcome. Th ese results probably refl ect an increased consumption of active 
AT due to the the extent of thrombosis (203). Th e elevated D-dimer levels 
on admission and 1 week aft er IS (Study IV) were strongly associated with 
stroke outcome and disability, supporting the results of two earlier reports 
(32, 88). In fact, elevated levels of D-dimer may refl ect the level of activation 
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of both the fi brinolytic and the coagulation systems, and thus, the ongoing 
thrombotic process. Th e other markers measuring coagulation, fi brinolysis, 
and vasoactivity (Studies I–IV) did not disclose information that could aid 
in identifying patients with poor prognosis. Th is fi nding indicates that there 
is considerably less activation of the fi brinolytic and coagulation systems in 
mild or moderately ill IS patients, corroborating previous reports (24, 47, 
189, 248). Interestingly, our follow-up examination of patients aft er stroke 
showed that F1+2 levels in the chronic phase (Study IV) had a positive 
correlation with recurrence of thromboembolic events and thus these marker 
may be used as a predictor of subsequent cerebral events, as also observed 
previously (61, 240). Th ese data support the idea that stroke patients with 
sustained activation of the blood coagulation system and increased thrombin 
generation of F1+2 levels may have an unfavorable prognosis.
No reports are available concerning a correlation between the presence 
of FVLm and stroke severity and prognosis. We found that stroke severity, 
outcome, and recurrence rates were not diff erent among FVLm-positive 
and -negative patients (Study V). However, a fi rm conclusion on this matter 
necessitates recruitment of a large number of consecutive patients, including 
those who die early or remain bedridden. Apparently, such patients are not 
considered prime targets for FVLm testing; those included herein were 
mostly young, vigorous patients without obvious etiologic factors for stroke, 
which explains the rather mild to moderate strokes observed.
Infl uence of markers measuring coagulation, fi brinolysis, 
and vasoactivity on radiological fi ndings (Studies II, V)
Th e hypothesis underlying Study II was that plasma Hcy levels promote 
brain injury aft er IS, thus increasing ischemic lesion size. Endres et al. (84) 
reported that elevated Hcy levels in folate-defi cient mice were associated 
with increased brain lesion size. We found no correlation between Hcy levels 
and brain infarction volumes.
Th e links between FVLm and radiological fi ndings have been examined 
in a few case-control studies, with contradictory results (208, 246). We 
recognized that the radiological fi ndings were nonspecifi c with regard to 
FVLm positivity and could not be used to show patterns indicative of FVLm. 
However, FVLm carriers more oft en had multiple ischemic lesions in brain 
images than FVLm-negative IS patients; in FVLm-positive patients, most 
infarctions were ‘silent infarcts’. Th is is a novel fi nding. Karttunen et al. (139) 
observed factor V Leiden or prothrombin G20210A mutation to be associated 
with cryptogenic stroke. Among patients with these prothrombotic states, 
the Valsalva maneuver was common at stroke onset. In our study, only 31 
patients with FVLm were evaluated to exclude PFO. Th us, we do not know 
whether multiple silent infarcts in brain images are related to an underlying 
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paradoxical embolism via PFO (139). No previous reports exist regarding 
a correlation between FVLm and leukoaraiosis. We found no signifi cant 
diff erences between FVLm-positive and -negative IS patients in the presence 
or degree of leukoaraiosis.
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Summary and conclusions
IS is a common and devastating disease frequently leading to death, disability, 
and suff ering. Evidence indicates increased thrombin generation and fi brin 
turnover, altered fi brinolytic activity, and disturbed endothelial function 
in IS. We hypothesized that changes in coagulation and fi brinolytic factors 
and in endothelial function would disclose patterns that might help in 
evaluating IS patients, including the early diagnosis of stroke subtypes, in 
estimating prognosis and risk of recurrence, and in selecting a treatment 
for secondary prevention of stroke. In Studies I–IV, we performed repeated 
measurements of markers assessing coagulation, fi brinolysis, and vasoactivity 
in a defi ned population of IS patients to shed light on these issues. In Study 
V, we examined IS patients with FVLm to determine whether the presence 
of FVLm was associated with specifi c clinical, laboratory, radiological, or 
prognostic characteristics.
All fi ve studies were carried out at the Department of Neurology, Helsinki 
University Central Hospital, aft er being approved by the Ethics Committee. 
One hundred and two IS patients were included in Studies I and II, and 55 
consecutive patients were chosen from this group for Studies III and IV. 
Another 42 patients were selected for Study V from 740 patients with IS 
without an obvious etiology. Patients underwent blood sampling four times, 
at each time point undergoing a full neurological evaluation, including 
several neurological scores, and assessment of multiple markers of endothelial 
and hemostatic function. Vasoconstrictor agent ET-1, Hcy, indicators of 
thrombin formation (F1+2), thrombin inactivation (TAT) and fi brinolysis 
(t-PA, PAI-1, and D-dimer), and natural anticoagulants (AT, PC, and PS) 
were measured. In addition, DNA analysis to determine whether FVLm was 
present was included. Short-term (3 months) and long-term (3 years) follow-
ups were performed to investigate stroke outcome and recurrence. During 
this study, 27–36% of patients were receiving anticoagulant therapy.
Repeated measurements of ET-1 or Hcy levels did not disclose any useful 
information. D-dimer and AT levels on admission and D-dimer levels at 1 
week were positively correlated with stroke outcome and disability. Our 3-
year follow-up examination showed that F1+2 level at 3 months aft er stroke 
had a positive correlation with recurrence of thrombotic events, and thus, 
this marker can used to predict recurrent IS. IS patients with heterozygous 
FVLm more oft en had a positive family history of thrombosis, a higher 
prevalence of peripheral vascular disease, and multiple infarctions in brain 
images, most of which were ‘silent infarcts’.
In summary, changes in markers measuring coagulation, fi brinolysis, and 
Summary and conclusions62
vasoactivity can be useful in estimating prognosis of IS patients. A clear 
need exists for a randomized prospective study to determine whether a 
subgroup of IS patients with markers indicating activation of fi brinolytic 
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